a research paper on cancer

Treatment Research

A new cellular immunotherapy approach shrank tumors in 3 of 7 patients with metastatic colon cancer, in a small NCI clinical trial. Normal white blood cells from each patient were genetically engineered to produce receptors that recognize and attack their specific cancer cells.

When it comes to cancer drugs, researchers are moving away from a paradigm called the maximum tolerated dose. Instead, they’re focusing more on identifying doses that produce fewer side effects but are still effective against a person’s cancer.

Reshaping the cancer clinical trials infrastructure to overcome key bottlenecks will involve embracing technology and collaboration, and inviting innovation, explain NCI Director Dr. W. Kimryn Rathmell and NCI Special Advisor Dr. Shaalan Beg.

In a new study in mice, researchers showed they could enhance radiation therapy by boosting levels of the BAMBI protein in MDSC immune cells in the tumor microenvironment. After radiation, T cells flooded into the tumor and killed tumors elsewhere in the body.

In a clinical trial, people being treated for cancer who participated in virtual mind–body fitness classes were less likely to be hospitalized, and had shorter stays when they were hospitalized, than people who did not take the classes.

NCI’s James H. Doroshow, M.D., reflects on the accomplishments of NCI-MATCH, a first-of-its-kind precision medicine cancer trial, and gives an overview of three new successor trials: ComboMATCH, MyeloMATCH, and iMATCH.

A new study, conducted largely in mice, may help explain why a currently used molecular marker—called mismatch repair deficiency—doesn’t always work to predict which patients will respond to immunotherapies called immune checkpoint inhibitors.

New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.

A cancer-infecting virus engineered to tamp down a tumor’s ability to suppress the immune system shrank tumors in mice, a new study shows. The modified oncolytic virus worked even better when used along with an immune checkpoint inhibitor.

Despite recommendations, a new analysis shows few people with cancer undergo germline testing to learn if their cancer may have been caused by gene changes inherited from a parent. Germline testing can help doctors determine the best treatments for a patient and help identify people whose family members may be at higher risk of cancer.

ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.

A new study has compared three formulations of an mRNA vaccine designed to treat cancers caused by human papillomavirus (HPV) infections. All three vaccines showed promise in mice.

Researchers have identified a mechanism by which cancer cells develop specific genetic changes needed to become resistant to targeted therapies. They also showed that this process, called non-homologous end-joining (NHEJ), can potentially be disrupted.

For some people with cancer, is 6 months of immunotherapy the only treatment they might ever need? Or 4 weeks of immunotherapy followed by minor surgery? Results from several small clinical trials suggest these scenarios may be bona fide possibilities.

Two research teams have developed ways of overcoming barriers that have limited the effectiveness of CAR T-cell therapies, including engineering ways to potentially make them effective against solid tumors like pancreatic cancer and melanoma.

In people with cancer treated with immune checkpoint inhibitors, a rare, but often fatal, side effect is inflammation in the heart, called myocarditis. Researchers have now identified a potential chief cause of this problem: T cells attacking a protein in heart cells called α-myosin.

Researchers have modified a chemo drug, once abandoned because it caused serious gut side effects, so that it is only triggered in tumors but not normal tissues. After promising results in mice, the drug, DRP-104, is now being tested in a clinical trial.

Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.

Inflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.

NCI researchers are developing an immunotherapy that involves injecting protein bits from cytomegalovirus (CMV) into tumors. The proteins coat the tumor, causing immune cells to attack. In mice, the treatment shrank tumors and kept them from returning.

FDA has approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for nearly any type of advanced solid tumor with a specific mutation in the BRAF gene. Data from the NCI-MATCH trial informed the approval.

People with cancer who take immunotherapy drugs often develop skin side effects, including itching and painful rashes. New research in mice suggests these side effects may be caused by the immune system attacking new bacterial colonies on the skin.

Researchers have developed tiny “drug factories” that produce an immune-boosting molecule and can be implanted near tumors. The pinhead-sized beads eliminated tumors in mice with ovarian and colorectal cancer and will soon be tested in human studies.

Women are more likely than men to experience severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, a new study finds. Researchers hope the findings will increase awareness of the problem and help guide patient care.

Research to improve CAR T-cell therapy is progressing rapidly. Researchers are working to expand its use to treat more types of cancer and better understand and manage its side effects. Learn how CAR T-cell therapy works, which cancers it’s used to treat, and current research efforts.

Experts say studies are needed on how to best transition telehealth from a temporary solution during the pandemic to a permanent part of cancer care that’s accessible to all who need it.

Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.

A specific form of the HLA gene, HLA-A*03, may make immune checkpoint inhibitors less effective for some people with cancer, according to an NCI-led study. If additional studies confirm the finding, it could help guide the use of these commonly used drugs.

The success of mRNA vaccines for COVID-19 could help accelerate research on using mRNA vaccine technology to treat cancer, including the development of personalized cancer vaccines.

Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells, but scientists didn’t know why. Two new studies suggest that aneuploidy helps the cells survive treatments like chemotherapy and targeted therapies.

New research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found.

FDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.

In lab studies, the antibiotic novobiocin showed promise as a treatment for cancers that have become resistant to PARP inhibitors. The drug, which inhibits a protein called DNA polymerase theta, will be tested in NCI-supported clinical trials.

A drug called avasopasem manganese, which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests.

While doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.

Cholesterol-lowering drugs known as PCSK9 inhibitors may improve the effectiveness of cancer immune checkpoint inhibitors, according to studies in mice. The drugs appear to improve the immunotherapy drugs’ ability to find tumors and slow their growth.

Researchers have developed a nanoparticle that trains immune cells to attack cancer. According to the NCI-funded study, the nanoparticle slowed the growth of melanoma in mice and was more effective when combined with an immune checkpoint inhibitor.

A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.

Researchers are developing a new class of cancer drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells. This Cancer Currents story explores the research on these emerging therapies.

FDA has recently approved two blood tests, known as liquid biopsies, that gather genetic information to help inform treatment decisions for people with cancer. This Cancer Currents story explores how the tests are used and who can get the tests.

Cancer cells with a genetic feature called microsatellite instability-high (MSI-high) depend on the enzyme WRN to survive. A new NCI study explains why and reinforces the idea of targeting WRN as a treatment approach for MSI-high cancer.

Efforts to contain the opioid epidemic may be preventing people with cancer from receiving appropriate prescriptions for opioids to manage their cancer pain, according to a new study of oncologists’ opioid prescribing patterns.

The gene-editing tool CRISPR is changing the way scientists study cancer, and may change how cancer is treated. This in-depth blog post describes how this revolutionary technology is being used to better understand cancer and create new treatments.

FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

Patients with acute graft-versus-host disease (GVHD) that does not respond to steroid therapy are more likely to respond to the drug ruxolitinib (Jakafi) than other available treatments, results from a large clinical trial show.

NCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the capability to make CAR T cells, which has limited the ability to test them more broadly.

An experimental drug may help prevent the chemotherapy drug doxorubicin from harming the heart and does so without interfering with doxorubicin’s ability to kill cancer cells, according to a study in mice.

In people with blood cancers, the health of their gut microbiome appears to affect the risk of dying after receiving an allogeneic hematopoietic stem cell transplant, according to an NCI-funded study conducted at four hospitals across the globe.

A novel approach to analyzing tumors may bring precision cancer medicine to more patients. A study showed the approach, which analyzes gene expression using tumor RNA, could accurately predict whether patients had responded to treatment with targeted therapy or immunotherapy.

Bone loss associated with chemotherapy appears to be induced by cells that stop dividing but do not die, a recent study in mice suggests. The researchers tested drugs that could block signals from these senescent cells and reverse bone loss in mice.

Some experts believe that proton therapy is safer than traditional radiation, but research has been limited. A new observational study compared the safety and effectiveness of proton therapy and traditional radiation in adults with advanced cancer.

In people with cancer, the abscopal effect occurs when radiation—or another type of localized therapy—shrinks a targeted tumor but also causes untreated tumors in the body to shrink. Researchers are trying to better understand this phenomenon and take advantage of it to improve cancer therapy.

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.

Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.

FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.

A new NCI-supported study showed that altering cancer cell metabolism by feeding mice a diet very low in the nutrient methionine improved the ability of chemotherapy and radiation therapy to shrink tumors.

An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.

Researchers have identified a protein called CD24 that may be a new target for cancer immunotherapy. The protein is a ‘don’t eat me’ signal that prevents immune cells called macrophages from engulfing and eating cells.

Injecting cells undergoing necroptosis, a form of cell death, into tumors in mice kickstarted an immune response against the tumors, researchers have found. When combined with immunotherapy, the treatment was effective at eliminating tumors in mice.

Researchers have identified proteins that may play a central role in transforming T cells from powerful destroyers to depleted bystanders that can no longer harm cancer cells. The findings could lead to strategies for boosting cancer immunotherapies.

Did you know that NCI supports clinical trials of new treatments for pet dogs with cancer? Learn more about NCI’s comparative oncology studies and how they may also help people with cancer.

Researchers have discovered a potential way to turn on one of the most commonly silenced tumor-suppressor proteins in cancer, called PTEN. They also found a natural compound, I3C, that in lab studies could flip the on switch.

New findings from a clinical trial suggest that a single dose of radiation therapy may control painful bone metastases as effectively as multiple lower doses of radiation therapy.

The expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.

The investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.

A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.

Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Cancer – an overview

• PMID: 29952494

Cancer is characterized by proliferation of cells that have managed to evade central endogenous control mechanisms. Cancers are grouped according to their organ or tissue of origin, but increasingly also based on molecular characteristics of the respective cancer cells. Due to the rapid technological advances of the last years, it is now possible to analyze the molecular makeup of different cancer types in detail within short time periods. The accumulating knowledge about development and progression of cancer can be used to develop more precise diagnostics and more effective and/or less toxic cancer therapies. In the long run, the goal is to offer to every cancer patient a therapeutic regimen that is tailored to his individual disease and situation in an optimal way.

PubMed Disclaimer

Similar articles

• Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Kruglyak KM, Lin E, Ong FS. Kruglyak KM, et al. Adv Exp Med Biol. 2016;890:123-36. doi: 10.1007/978-3-319-24932-2_7. Adv Exp Med Biol. 2016. PMID: 26703802 Review.
• Tumor microenvironment and cancer therapy resistance. Sun Y. Sun Y. Cancer Lett. 2016 Sep 28;380(1):205-15. doi: 10.1016/j.canlet.2015.07.044. Epub 2015 Aug 10. Cancer Lett. 2016. PMID: 26272180 Review.
• The evolving potential of companion diagnostics. Khoury JD. Khoury JD. Scand J Clin Lab Invest Suppl. 2016;245:S22-5. doi: 10.1080/00365513.2016.1206444. Epub 2016 Jul 19. Scand J Clin Lab Invest Suppl. 2016. PMID: 27433788
• Anticancer Drug Combinations, How Far We can Go Through? Lu DY, Chen EH, Wu HY, Lu TR, Xu B, Ding J. Lu DY, et al. Anticancer Agents Med Chem. 2017;17(1):21-28. Anticancer Agents Med Chem. 2017. PMID: 27039923 Review.
• Drug Combination in Clinical Cancer Treatments. Lu DY, Lu TR, Yarla NS, Wu HY, Xu B, Ding J, Zhu H. Lu DY, et al. Rev Recent Clin Trials. 2017;12(3):202-211. doi: 10.2174/1574887112666170803145955. Rev Recent Clin Trials. 2017. PMID: 28782482 Review.
• Precision Nutrition Unveiled: Gene-Nutrient Interactions, Microbiota Dynamics, and Lifestyle Factors in Obesity Management. Mansour S, Alkhaaldi SMI, Sammanasunathan AF, Ibrahim S, Farhat J, Al-Omari B. Mansour S, et al. Nutrients. 2024 Feb 20;16(5):581. doi: 10.3390/nu16050581. Nutrients. 2024. PMID: 38474710 Free PMC article. Review.
• Abscopal Effect, Extracellular Vesicles and Their Immunotherapeutic Potential in Cancer Treatment. Salazar A, Chavarria V, Flores I, Ruiz S, Pérez de la Cruz V, Sánchez-García FJ, Pineda B. Salazar A, et al. Molecules. 2023 Apr 29;28(9):3816. doi: 10.3390/molecules28093816. Molecules. 2023. PMID: 37175226 Free PMC article. Review.
• Circ_0001658 regulates PI3K/AKT signaling via the miR-671-5p/ITGA2 axis and affects the progress of papillary thyroid carcinoma. Liu X, Wang C, Su Z, Cai S, Pan Q, Chen X. Liu X, et al. Ann Transl Med. 2022 Sep;10(18):1001. doi: 10.21037/atm-22-3650. Ann Transl Med. 2022. PMID: 36267792 Free PMC article.
• Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer. Al-Ishaq RK, Koklesova L, Kubatka P, Büsselberg D. Al-Ishaq RK, et al. Cancers (Basel). 2022 Apr 25;14(9):2140. doi: 10.3390/cancers14092140. Cancers (Basel). 2022. PMID: 35565269 Free PMC article. Review.
• Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancer. Nwafor EO, Lu P, Zhang Y, Liu R, Peng H, Xing B, Liu Y, Li Z, Zhang K, Zhang Y, Liu Z. Nwafor EO, et al. Transl Oncol. 2022 Jan;15(1):101294. doi: 10.1016/j.tranon.2021.101294. Epub 2021 Nov 30. Transl Oncol. 2022. PMID: 34861551 Free PMC article. Review.

Publication types

• Search in MeSH
• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

• Editorial board
• About this journal
• Author info
• Submit manuscript
• Manuscript login
• Current issue
• Volume 15; 2024
• Volume 14; 2023
• Volume 13; 2022
• Volume 12; 2021
• Volume 11; 2020
• Cover images
• Index & coverage
• Special issues

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Research Paper Development and Validation of an Interpretable Machine Learning Prediction Model for Total Pathological Complete Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: Multicenter Retrospective Analysis Ziran Zhang, Bo Cao, Jinghua Wu, Chengtian Feng J. Cancer 2024; 15(15): 5058-5071. doi:10.7150/jca.97190 Full text PDF

Research Paper Prognostic role of immunohistochemical PTEN (phosphatase and tensin homolog) expression and PTEN (rs701848) genotypes among Egyptian patients with different stages of colorectal cancer Heba Ahmed Osman, Mohammed H. Hassan, Abdelaziz Mostafa Toema, Amira A. Abdelnaby, Mahmoud A. Abozeid, Mohamed Abdelshafy Mohamed, Abdelkader Ahmed Hashim, AbdAlraheem Husein, Abdelazeem E. Ahmed, Sameh Salaheldin Elsayed, Sherief El-Ghannam, Marwa Abdelhady, Ghada M. Abdelrazek J. Cancer 2024; 15(15): 5046-5057. doi:10.7150/jca.97553 Full text PDF

Research Paper Screening of PDSS1 as a Potential Biomarker for Hepatocellular Carcinoma Based on a Copper-Related Prognostic Signature through Bulk and Single-cell RNA-sequencing Analysis Kainan Lin, Jingwei Cai, Siyuan Pan, Xuefei Yu, Yiwu Qiu, Zhangguo Ying, He Feng, Lizhuo Zhang, Yanyang Liu, Huize Shen, Yangjian Hong, Qinglin Li, Renan Jin J. Cancer 2024; 15(15): 5028-5045. doi:10.7150/jca.96867 Full text PDF

Research Paper The impact of tumor size on the prognosis and chemotherapy efficacy in stage I/II colon cancer patients Jiahe Yang, Shichao Li, Yulu Zhao, Fangyuan Yang, Qian Wang, Lan Ding, Cheng Chen, Xiaoyuan Chu J. Cancer 2024; 15(15): 5020-5027. doi:10.7150/jca.95743 Full text PDF

Research Paper CXCL1 promotes cell migration in hepatocellular carcinoma by regulating the miR-30b-5p/ICAM-1 axis Yi-Hsin Chen, Chih-Chun Chu, Augusta I-Chin Wei, Ju-Fang Liu, Hong-Shiee Lai J. Cancer 2024; 15(15): 5007-5019. doi:10.7150/jca.95816 Full text PDF

Research Paper Prognostic and immunotherapeutic significances of M2 macrophage-related genes signature in lung cancer Haixia Wu, Yilin Yu, Wei Wang, Gen Lin, Shaolin Lin, Jiguang Zhang, Zhaojun Yu, Jiewei Luo, Deju Ye, Wu Chi, Xing Lin J. Cancer 2024; 15(15): 4985-5006. doi:10.7150/jca.98044 Full text PDF

Research Paper Bidirectional Mendelian Randomization of Causal Relationship between Inflammatory Cytokines and Different Pathological Types of Lung Cancer Xinhang Hu, Shouzhi Xie, Xuyang Yi, Yifan Ouyang, Wangcheng Zhao, Zhi Yang, Zhe Zhang, Li Wang, Xingchun Huang, Muyun Peng, Fenglei Yu J. Cancer 2024; 15(15): 4969-4984. doi:10.7150/jca.98301 Full text PDF

Research Paper Unlocking the Therapeutic Potential: Harnessing miR-125a-5p To Enhance Autophagy and Apoptosis in Pancreatic Cancer through Targeting STAT3 Lujuan Pan, Zongshuai Qin, Qinghong Zhou, Pin Zheng, Hua Li, Xihan Zhou, Yueqiu Qin J. Cancer 2024; 15(15): 4955-4968. doi:10.7150/jca.97102 Full text PDF

Indexed in PubMed and SCI expanded; full texts in PubMed Central and Europe PMC . ...

A note on plagiarism (please read before submission) : There is a zero-tolerance policy towards plagiarism in this journal. Manuscripts are screened for plagiarism at any stages. If a manuscript is already published and plagiarism is still detected or later reported by readers, it will be retracted and the authors' institutions and department heads will be notified to take actions. This includes data fabrication and image manipulation.

Research Paper The impact of Elaeagnus angustifolia root exudates on Parafrankia soli NRRL B-16219 exoproteome Ikram kammoun, Guylaine Miotello, Karim Ben Slama, Jean Armengaud, Faten Ghodhbane-Gtari, Maher Gtari J. Genomics 2024; 12: 58-70. Full text PDF PubMed PMC

JCA Top cited papers:

• Anahid Jewett, et al. Dual Functions of Natural Killer Cells in Selection and Differentiation of Stem Cells; Role in Regulation of Inflammation and Regeneration of Tissues. Cited by 62
• Jan Trøst Jørgensen, Maria Hersom.  HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. Cited by 204
• Chikezie O. Madu, Yi Lu . Novel diagnostic biomarkers for prostate cancer. Cited by 223
• Ohtani H, et al. A meta-analysis of the short-and long-term results of randomized controlled trials that compared laparoscopy-assisted and conventional open surgery for colorectal cancer. Cited by 167
• Dario Sangiolo . Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors. Cited by 193
• Sara A. Lari, Henry M. Kuerer . Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. Cited by 131

©2024 Ivyspring International Publisher . Terms of use

• Molecular Methods
• Genetic Engineering
• Biological Science
• Molecular Biology
• Genetic Techniques
• Genetic Therapy
• Gene Therapy

cancer: an overview

• January 2015
• Academic Journal of Cancer Research 8(1):01-09

• Galgotias University

Discover the world's research

• 25+ million members
• 160+ million publication pages
• 2.3+ billion citations
• Nikita Pandit

• Sujoy K. Chaudhury
• ACTA CHIM SLOV

• RES J BIOTECHNOL
• Madhavi Latha Duda
• Amarnath Velidandi
• Shyam Prasad Gurram

• Babatunde Yusuf Raimi
• Samuel Omokhafe Yusuf
• Chisom Assumpta Nnajiofor

• Hesam Noqani

• J DRUG DELIV SCI TEC

• Shweta Arora
• Sagarika DHAMNE

• S. K. Reshmi

• C. Anandharamakrishnan

• J K McLaughlin
• Deborah M Winn
• Joseph F. Fraumeni
• BRIT MED BULL

• Kenneth C. Chu
• Robert E. Tarone
• Wong-Ho Chow

• Yucheng Tang
• Guanxiang Qian
• Emmanuel Mitry

• David C. Miller
• S Lilly Zheng
• Rodney L Dunn

• K B Harikumar
• S T Tharakan
• B B Aggarwal
• S P Agarwal
• S Gupta Althuis
• W F Anderson
• India Government
• C Mathers Ravdin
• Recruit researchers
• Join for free
• Login Email Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google Welcome back! Please log in. Email · Hint Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google No account? Sign up

Cancer diagnosis can be devastating, but for some it gives permission to live more radically

Professor of Sociology, Te Herenga Waka — Victoria University of Wellington

Professor of Sociology & Director, Sydney Centre for Healthy Societies, University of Sydney

Professor of Maori & Public Health, Te Kunenga ki Pūrehuroa – Massey University

Associate Professor in Surgery, University of Otago

Professor of Social and Health Psychology, Te Kunenga ki Pūrehuroa – Massey University

Associate Professor in Health Promotion, University of Otago

Disclosure statement

Kevin Dew receives funding from The Marsden Fund..

Alex Broom receives funding from the Australian Research Council.

Kerry Chamberlain receives funding from the Marsden Fund.

Chris Cunningham, Elizabeth Dennett, and Richard Egan do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Te Herenga Waka — Victoria University of Wellington , Te Kunenga ki Pūrehuroa – Massey University , and University of Otago provide funding as members of The Conversation NZ.

University of Sydney , Te Herenga Waka—Victoria University of Wellington , University of Otago , and Te Kunenga ki Pūrehuroa – Massey University provide funding as members of The Conversation AU.

View all partners

A diagnosis of life-limiting cancer can be overwhelming and cause feelings of panic and anxiety. But for some people, it provides a license to live life differently, including quitting toxic jobs and becoming more adventurous.

In our recently published research , we sought to understand the impact of a cancer diagnosis and subsequent experiences for cancer survivors.

We talked with 81 New Zealanders (23 Māori and 58 non-Māori) who had lived longer than expected with a life-limiting or terminal diagnosis of cancer (four to 32 years since first diagnosis), and 25 people who were identified as their supporters.

We found there are vastly different ways in which people experience and respond to a cancer diagnosis, but for some it’s a prompt to make significant changes. Of the 81 participants, 26 expressed the view, unsolicited, that cancer had some positive impact on their lives – without downplaying the negative impacts it could have as well.

A licence to change

Being told you only have limited time left to live can undoubtedly be a shock. But it can lead to profound change.

It’s not uncommon for people who receive a serious diagnosis to draw up a “ bucket list ”. Some people in our study took the opportunity to travel or move to a new home.

For others, the diagnosis provided a chance to rethink their lives and make more significant changes to the way they lived. They decided to be culturally more adventurous and to take up new skills.

Many of these people quit their jobs or changed to jobs that suited them better. Many changed their relationships with the people around them. One talked about showing more affection for his children, another was kinder and stopped fretting over small things.

Some decided to be more selective and no longer be around people who were negative. Others took up new hobbies or crafts which they felt were healing. For one person, the cancer diagnosis provided the impetus to look at things and people differently, which they thought would not have happened otherwise.

Individuals could also undergo a transformation to become what they felt they were meant to be in life. One person, given two months to live, embraced rongoā (Māori traditional healing), including its spiritual side. They now love their “journey” and feel this was what they were “supposed to do”.

For many, a diagnosis of cancer gave them license to be different people and to resist conforming to social norms, including having a job, being thrifty or not taking risks.

Disrupting diagnoses

One person, given only months to live, moved out of her flat, gave away her possessions, quit her job that she described was toxic, and returned home to say goodbye to her family.

Most importantly for her, she worked on experiencing “joy” – after receiving the diagnosis, she realised she had lost it. But she continues to live many years later. After a while, she had to find a new flat, get a new job and the recovery of her joy was challenged:

I had to start working again. And, of course, with working again, joy goes down, time goes down, rest goes down, spirituality goes down.

But not everyone has the opportunity to change. Some peoples’ lives were limited because of the physical effects of the cancer, its treatment, or because of their personal, social or financial resources.

Some go to great lengths to ensure their lives change as little as possible after diagnosis to maintain a sense of normality.

Why we need to know

Given the fear a cancer diagnosis can elicit, it is important to see there are different ways of responding.

It is also worth knowing there are people who live longer than expected. Many people in our study were given just months to live, but one woman was still alive 12 years after being told she had a year left.

Beyond that, this research documents how the disruption produced by a cancer diagnosis can prompt people to breach social norms. Where people have the capacity and resources to change, those around them and their health professionals can support them in taking opportunities to live life differently.

We heard people say they think of their cancer as a friend or an amazing opportunity. Some even felt thankful.

The possibility of cancer providing opportunities for some in no way diminishes the grief or a sense of loss, fear and anxiety that can accompany such diagnoses.

Our research supports a reframing of cancer narratives, to consider ways of tempering the negative impacts of a diagnosis – while remaining cognisant of the struggle that can follow such news, and the variability in people’s capacity to engage with that struggle.

• New Zealand
• Cancer diagnosis
• Cancer survival

Sydney Horizon Educators – Faculty of Engineering (Targeted)

Communications and Change Manager – Research Strategy

Head of School: Engineering, Computer and Mathematical Sciences

Educational Designer

Organizational Behaviour – Assistant / Associate Professor (Tenure-Track)

• Adolescent and Young Adult Cancer
• Bile Duct Cancer
• Bladder Cancer
• Brain Cancer
• Breast Cancer
• Cervical Cancer
• Childhood Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Head and Neck Cancer
• Kidney Cancer
• Liver Cancer
• Lung Cancer
• Mouth Cancer
• Mesothelioma
• Multiple Myeloma
• Neuroendocrine Tumors
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Skin Cancer/Melanoma
• Stomach Cancer
• Testicular Cancer
• Throat Cancer
• Thyroid Cancer
• Prevention and Screening
• Diagnosis and Treatment
• Research and Clinical Trials
• Survivorship

Request an appointment at Mayo Clinic

Living with cancer: Guidance from Mayo Clinic experts

Share this:.

By Mayo Clinic staff

Whether cancer runs in your family or you've recently been diagnosed with the disease, living with cancer can be hard. Every day at Mayo Clinic, healthcare professionals care for people who face this reality.

A group of these Mayo Clinic cancer experts helped create a series of short videos sharing their guidance on how to cope with the challenges of life with cancer. These videos feature advice from these experts:

• Judy C. Boughey, M.D. , a surgical oncologist.
• Shawna L. Ehlers, Ph.D. , a psychologist and psycho-oncology expert.
• Joy R. Heimgartner, a dietitian specializing in cancer nutrition.
• Dawn M. Mussallem, D.O. , an integrative health and breast cancer specialist.
• Mabel Ryder, M.D. , an endocrinologist.
• Adam M. Shultz, an exercise physiologist.

Each video is no more than two minutes long. Watch one now:

When cancer runs in your family

Worried about a family history of cancer? Hear Mayo Clinic experts Dr. Dawn Mussallem, Dr. Shawna Ehlers and Adam Shultz offer advice on managing your risk — and your worry.

Why goals matter during cancer treatment

What's most important to you? Hear Mayo Clinic experts Dr. Mabel Ryder, Dr. Judy Boughey and Dr. Shawna Ehlers share why your answer matters when creating a cancer treatment plan.

How to talk about a cancer diagnosis

Patients often ask Dr. Shawna Ehlers how to talk to friends and family about a cancer diagnosis. Here's what she tells them.

Why you should accept help when you have cancer

Dr. Shawna Ehlers calls cancer a team sport. Learn why she says asking for help is important for patients and loved ones.

Tips on what to eat during cancer treatment

Your appetite changes during cancer treatment. Learn how to plan for changes from Joy Heimgartner.

Exercise during cancer treatment

Staying active is one of the best things you can do for yourself during cancer treatment. Hear Adam Shultz discuss the benefits.

Learn more about coping with cancer by reading these articles:

• Surviving cancer: What to expect after the diagnosis
• Cancer diagnosis: 11 tips for coping
• Cancer fatigue: Why it occurs and how to cope
• Cancer pain: Relief is possible
• Cancer survivors: Managing your emotions after cancer treatment
• When cancer returns: How to cope with cancer recurrence

Join the Cancer Support Group on Mayo Clinic Connect , an online community moderated by Mayo Clinic for patients and caregivers.

Learn about the free education and resources offered to cancer patients at all Mayo Clinic sites by the Stephen and Barbara Slaggie Family Cancer Education Center.

Related Posts

Emily McTate, Ph.D., discusses how pediatric psychology can proactively support childhood development during and after cancer diagnosis and treatment.

Rebecca Kath, a Mayo Clinic physician assistant, explains how 3D tattoos are used to restore the appearance of nipples and areolas.

Kirk honored his experience with sarcoma and his care team with a series of tattoos that continue to spark conversations.

New study led by our partners at the American Cancer Society suggests incidence rates continue to rise in younger generations for many cancers. Read our breakdown of the findings.

News & Articles

Cancer Trends in Younger Adults: Insights from Recent Research

Scott Topper, PhD

Cancer has traditionally been seen as a disease that affects older adults, but that is changing.

Today, our partners at the American Cancer Society published a comprehensive review of 20 years of cancer data, to show clearly that rates of certain cancers are increasing in younger adults . While pieces of this trend have been reported previously, today’s analysis from Hyuna Sung and colleagues, published in The Lancet Public Health, provides the fullest and most comprehensive picture to date. This important paper cements our certainty that these trends are real, illustrates the breadth of cancers included in this trend, and raises important questions about the future. With the incidence of cancer in the young on the rise, the overall costs of treating and managing cancer and its after effects are likely to get worse than they already are, further straining an already strained healthcare system.

Their results are startling and concerning.

What did they find?

The study revealed several critical trends:

50% of the cancers analyzed (17 of 34) show an increased incidence in younger people. 

The incidence of some cancers are more than 2x higher in young people compared to people born in 1955. In some cases, the trend seems to be getting worse over time, with progressively higher incidence rates in younger and younger cohorts. These cancers include small intestine cancer, kidney and renal pelvis cancer, pancreatic cancer, and liver cancers in females. This represents a dramatic increase.

The incidence of other cancers are also increasing, including some which had previously shown a downward trend. These include estrogen-receptor-positive breast cancer, uterine corpus cancer, colorectal cancer, non-cardia gastric cancer, gallbladder, ovarian, testicular cancer, anal cancer in males, and Kaposi sarcoma in males. 

A few cancers show increased mortality rates as well.  

These include liver cancer, uterine corpus cancer, gallbladder cancer, testicular cancer, and colorectal cancers. However, for most cancer types, mortality rate ratios (MRRs), a measure of the mortality rate of a given cancer, either declined or stabilized in younger cohorts.

What factors are causing the increase?

It’s not completely clear, but there are hints.

The authors make a strong case that these trends are related to exposures to risk factors that are experienced similarly by people born around the same time, at the same time in their lives. Their careful statistical analysis was designed to control for things that would impact all ages similarly, for example improvements in detection or treatment. Interestingly, a few of the most positive findings in the paper make the case most strongly that environmental factors are largely at play– cases where we see, thankfully, a reduction in cancer incidence in younger people.

10 of the 17 cancers that are increasing in incidence are known to be obesity-related, including colorectal cancer, uterine corpus cancer, gallbladder and other biliary cancer, kidney and renal pelvis cancer, and pancreatic cancer. Some of these associations have been previously established, but the scale and scope of the impact is striking to see. We know that obesity has been on the rise in the US since the 1970s across all age groups, but has been most severe among younger people. We also know that the influence of bodyweight during early adulthood can increase the risk of cancer generally as well as other cardiometabolic conditions. 

The authors summarize other emerging theories that might explain these trends. Sedentary lifestyles during adolescence and young adulthood have been associated with an increased risk for colorectal and breast cancers. Some people suggest that changes in dietary patterns and antibiotic use lead to an altered microbiome, which could lead to increased risk of certain gastrointestinal cancers. Additionally, a reduction in oral contraceptive use from 1970s – 1990s may have contributed to the increase in ovarian cancer risk. 

What is clear is that understanding these trends is crucial for shaping effective public health strategies. If the risk factors are environmental, it suggests that they are modifiable. Future research should explore early-life exposures and their long-term impact on cancer risk. Longitudinal studies are needed to understand the role of environmental and genetic factors in these trends.

What does this mean for healthcare?

This paper demonstrates that cancer is not a problem we can wish away, or will be rid of soon. We will all be living with the impacts of these trends for decades to come. In the simplest terms, it means that we can anticipate more, and younger, cancer patients. As, for the most part, mortality rates have remained stable or continued to decline, it means that we can also anticipate more cancer survivors, for longer. Finding these people, and supporting them on that road through screening, diagnosis, treatment, and recovery, will become even more important. 

Early detection matters more than ever. We know the cost of treating cancer increases and the likelihood of surviving cancer decreases if the cancer is caught too late. We also know that cancer screening just isn’t on the radar for many young people or on the mind of their doctors. Mechanisms to simplify the process of developing and deploying screening protocols across younger, working age people, and effective protocols for following up on abnormal findings in a fast and cost-effective way, can have an outsize impact on minimizing the cost of these trends and on saving lives. 

Finally, all of us– from healthcare systems, to employers, to families– will have to adapt to address the unique needs of younger cancer patients, who may face different challenges compared to older patients. This includes addressing issues related to fertility, long-term survivorship, and psychosocial support.

The importance of this study by Hyuna Sung and the American Cancer Society cannot be overstated. We can learn to manage what we can see, and if we can better predict the future cancer burden we can better mitigate it, ultimately improving public health outcomes. This paper helps us direct our energy and intelligence towards driving outcomes that can buy decades of productive life.

Other related articles

Using AI to Accelerate Cancer Diagnosis to Treatment Time for Your Workforce

Bringing cancer expertise to a doctor near you: Color’s copilot and partnership with OpenAI

Demystifying New Diagnostic Technology in Cancer Detection: Q&A With Alicia Zhou and Dr. Bill Dahut

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Published: 19 April 2022

Focus Issue: The Future Of Cancer Research

Nature Medicine volume  28 ,  page 601 ( 2022 ) Cite this article

14k Accesses

6 Citations

9 Altmetric

Metrics details

New treatments and technologies offer exciting prospects for cancer research and care, but their global impact rests on widespread implementation and accessibility.

Cancer care has advanced at an impressive pace in recent years. New insights into tumor immunology and biology, combined with advances in artificial intelligence, nano tools, genetic engineering and sequencing — to name but a few — promise ever-more-powerful capabilities in the prevention, diagnosis and personalized treatment of cancer. How do we harness and build on these advances? How do we make them work in different global settings? In this issue, we present a Focus dedicated to the future of cancer research, in which we take stock of progress and explore ways to deliver research and care that is innovative, sustainable and patient focused.

This year brought news that two of the first patients with leukemia to receive chimeric antigen receptor (CAR) T cell treatment remain in remission more than a decade later . Writing in this issue, Carl June — who helped to treat these first patients — and colleagues reflect on how early transplant medicine laid a solid foundation for CAR T cell development in blood cancers, and how this is now paving the way for the use of engineered cell therapies in solid cancers. In a noteworthy step toward this goal, Haas and colleagues present results of a phase 1 trial of CAR T cells in metastatic, castration-resistant prostate cancer — a disease that has seen relatively few new treatment options in recent years.

Up to now, CAR T cells have been used only in the context of relapsed or refractory hematological malignancies, but in this issue, Neelapu et al . present phase 2 study data that suggest CAR T cell therapy could be beneficial when used earlier in certain high-risk patients. In addition, prospective data from van den Brink et al . support a role for the gut microbiome composition in CAR T cell therapy outcomes, highlighting new avenues of research to help maximize therapeutic benefit.

Although the idea that the gut microbiome influences CAR T cell therapy outcomes may be relatively new, it has been known for some time that it has a role in the response to checkpoint-inhibitor immunotherapy. A plethora of microbe-targeting therapies are now under investigation for cancer treatment; in this issue, Pal and colleagues describe one such strategy — whereby the combination of a defined microbial supplement with checkpoint blockade led to improved responses in patients with advanced kidney cancer. In their Review, Jennifer Wargo and colleagues take stock of the latest research in this field, and predict that microbial targeting could become a pillar of personalized cancer care over the next decade.

The theme for this year’s World Cancer Day was ‘Close the care gap’ — a message that is woven through several pieces in this issue. Early detection strategies have enormous potential to make a difference in this area; reviewing the latest advances, Rebecca Fitzgerald and colleagues ask who should be tested, and how — and outline their vision for personalized, risk-based screening, keeping in mind practicality and clinical implementation. Journalist Carrie Arnold reports on an emerging strategy known as ‘theranostics’ that aims to both diagnose and treat cancers in a unified approach, highlighting the growing commercial interest in this field. Of course, commercial interest does not equate to widespread availability or equal access to new therapies, and increasingly sophisticated technologies — although beneficial for some — can serve to widen existing inequalities.

Pediatric cancers lag far behind adult cancers in terms of drug development and approval. Nancy Goodman, a patient advocate whose son died from a childhood cancer, argues that market failures are largely to blame for the gap — but that legislative changes can correct this. Although in some cases there is a strong mechanistic rationale for testing promising adult cancer therapies or combinations in children, translational research is also needed to identify new therapeutic targets — such as the approach taken by Behjati and colleagues , which sheds new light on the molecular characteristics of an aggressive form of infant leukemia.

Meanwhile, for adult cancers, countless new therapeutic modalities are on the horizon , and drug approvals based on genomic biomarkers have accelerated in recent years. Unfortunately, their implementation into routine clinical care is progressing at a much slower pace. In their Perspective, Emile Voest and colleagues point out that bridging this gap will require investment in health infrastructure, as well as in education and decision-support tools, among other things.

Perhaps the most striking gap is that between high-income countries and low- and middle-income countries, not only in terms of cancer survival outcomes but also in terms of resources and infrastructure for impactful research. In their Perspective, CS Pramesh and colleagues outline their top priorities for cancer research in low- and middle-income countries, arguing that cancer research must be regionally relevant and geared toward reducing the number of patients diagnosed with advanced disease. Practicality is key — a sentiment echoed by Bishal Gyawali and Christopher Booth, who call for a “ common sense revolution ” in oncology, and regulatory policies and trial designs that serve patients better.

To realize this goal, clinical trial endpoints and outcome measures should be designed to minimize the burden on patients and maximize the potential for improving on the standard of care. This should go beyond survival outcomes; systemic effects, including cachexia and pain, have a major impact on quality of life and mental health during and after treatment. Two articles in this issue highlight the enormous psychological burden associated with a cancer diagnosis; increased risks of depression, self-harm and suicide emphasize the need for psychosocial interventions and a holistic approach to treatment.

As noted by members of the Bloomberg New Economy International Cancer Coalition in their Comment , the widespread adoption of telemedicine and remote monitoring in response to the COVID-19 pandemic could, if retained, help to make cancer trials more patient centered. Therefore, as health systems and research infrastructures adapt to the ongoing pandemic, there exists an unprecedented opportunity to reshape the landscape of cancer research.

We at Nature Medicine are committed to helping shape this transformation. We are issuing a call for research papers that utilize innovative approaches to address current challenges in cancer prevention, detection, diagnosis and treatment — both clinical trials and population-based studies with global implications. Readers can find more information about publishing clinical research in Nature Medicine at https://www.nature.com/nm/clinicalresearch .

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Focus Issue: The Future Of Cancer Research. Nat Med 28 , 601 (2022). https://doi.org/10.1038/s41591-022-01809-z

Download citation

Published : 19 April 2022

Issue Date : April 2022

DOI : https://doi.org/10.1038/s41591-022-01809-z

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Nanotheranostics
• v.6(4); 2022

Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview

Sareh mosleh-shirazi.

1 Department of Materials Science and Engineering, Shiraz University of Technology, Shiraz, Iran

Milad Abbasi

2 Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad reza Moaddeli

3 Assistant Professor, Department of Oral and Maxillofacial Surgery, School of Dentistry, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

4 Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

Mostafa Shafiee

Seyed reza kasaee.

5 Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Ali Mohammad Amani

Saeid hatam.

6 Assistant Lecturer, Azad University, Zarghan Branch, Shiraz, Iran

7 ExirBitanic, Science and Technology Park of Fars, Shiraz, Iran

Over the last few years, progress has been made across the nanomedicine landscape, in particular, the invention of contemporary nanostructures for cancer diagnosis and overcoming complexities in the clinical treatment of cancerous tissues. Thanks to their small diameter and large surface-to-volume proportions, nanomaterials have special physicochemical properties that empower them to bind, absorb and transport high-efficiency substances, such as small molecular drugs, DNA, proteins, RNAs, and probes. They also have excellent durability, high carrier potential, the ability to integrate both hydrophobic and hydrophilic compounds, and compatibility with various transport routes, making them especially appealing over a wide range of oncology fields. This is also due to their configurable scale, structure, and surface properties. This review paper discusses how nanostructures can function as therapeutic vectors to enhance the therapeutic value of molecules; how nanomaterials can be used as medicinal products in gene therapy, photodynamics, and thermal treatment; and finally, the application of nanomaterials in the form of molecular imaging agents to diagnose and map tumor growth.

Introduction

Oncologists worldwide, use a variety of treatments, including radiation therapy, surgery, and chemotherapy, to treat cancer patients 1 . But the treatment of a tumor tissue demands dealing with plenty of limitations that urge the increasing interest in the use of Nanomaterials. Over the last decade, increased knowledge of the microenvironment of tumors has motivated our efforts to develop nanoparticles as a novel cancer-related therapeutic and diagnostic strategy 2 . Cancer tissues consist of non-cellular (e.g. interstitial and vascular) or cellular compartments which vary considerably from the healthy tissues around them. Each of these compartments presents a challenge for the delivery of drugs to tumor cells locally (Figure ​ (Figure1) 1 ) 3 , 4 . However, tumor therapy through conventional methods brings more affordable choices for patients and many scientists still work on Click Chemistry-derived simple organic molecules such as Acridone to simplify the treatment procedure. On the other hand, it looks unavoidable to develop more efficient and less time-consuming treatments involved with nanostructures because of difficult delivery, low bioavailability, transportation issues, and hazards related to conventional drug molecules 5 .

The tumoral microenvironment. Angiogenesis is due to tumor cell release agents (e.g. bradykinin, vascular endothelial growth factor (VEGF), nitric oxide (NO), and prostaglandin (PG) that induce the development of fresh blood vessels (Top left). Tumor heterogeneity is seen in regions of tumor necrosis or tumor perfusion that contain active tumor cells that are strong and weak (Top Right). Representation of tumor cell drug resistance through the protein pumps responsible for removing chemotherapy drugs from the cell. Also, insufficient lymphatic cell penetration to tumor tissue (Bottom). Created with BioRender.com

Tumor vascularity is distinctly heterogeneous within its non-cellular composition. This includes extremely avascular regions that absurdly supply nutrients and oxygen for the rapid development of tumor components since tumor necrotic areas have a very limited blood supply. Tumor cells that are isolated far off the vascular system, as mentioned, have a reduced amount of oxygen available; this is mainly due to the additional gap between the tumor cells for which oxygen is to be distributed and also to the higher consumption of oxygen within the tumor cells that are closer to the circulatory system 6 , 7 . In a mechanism called angiogenesis, fresh blood vessels are reproducing around tumors; however, such vessels are abnormal with elevated percentages of endothelial cell proliferation, increased vascular tortuosity, and lack of pericytes. Also, there are considerable distances across the basement membrane between adjacent endothelial cells that vary from 380 to 780 nm. Bradykinin, prostaglandin and nitric oxide, vascular endothelial growth factors, are all up-regulated while resulting in a hyper permeable tumor cell condition (Figure ​ (Figure1) 1 ) 8 , 9 .

The interstitial environment, consisting of an elastic and collagen fiber network, surrounds the tumor cells. Tumor interstitium contains extreme intercellular stress and often a comparative lack of lymphatic activity in these areas, as opposed to regular tissues, which minimizes the extravagance of vasculature medications due to increased interstitial pressure around it 10 .

Overall, getting to know non-cellular pathways of drug tolerance appears to be necessary for the following reasons. The decrease in accessible oxygen due to the unavailability of the vasculature contributes to the acidic microenvironment resulting from the anaerobic glycolysis accumulation of lactic acid and, in particular, to the tolerance of simple ionized drugs, thus prohibiting their spread through cell membranes 11 , 12 .

Scientific investigations have demonstrated that there are two distinct cell populations within the tumor: a relatively small, unusual, and quiet group known as cancer stem cells (CSCs) and a larger group of rapidly proliferating cells that make up the bulk of the tumor mass 13 . While non-CSCs will not be metastatic or self-sustaining, CSCs can not only reconstruct the tumor but also maintain cell migration (e.g. metastases and invasion) and self-protection genetic machinery. This keeps the CSCs behind, which then rebuilds the tumor because most chemotherapy drugs mainly target non-CSCs which reveals why cancers sometimes recur after surgery 14 . Experimental drugs are therefore directly tailored to CSCs, which are now considered to be the key objective of therapeutic intervention. Death of CSCs, avoids local recurrence and metastases, and would thoroughly destroy cancer cells. In addition, it has also been shown that the microenvironment surrounding the CSCs regulates their proliferation, as well as their cell-fat functions, enabling tumors to demonstrate their total neoplastic phenotype. Another strategy for treating and attempting to control cancer progression could be techniques for modifying nonmalignant cells across the microenvironment 15 , 16 . One of the objectives of nano-delivery of drugs is to control the tumor-associated macrophages (TAMs), triggered by chemokines and other growth factors (e.g. colony-stimulating factor-1) provided by tumor cells to the mass of the tumor. TAMs are abundant throughout the solid tumor stroma and have been shown to intensify tumor development by facilitating the migration and invasiveness of tumor angiogenesis. This confirms the strong association between increased TAM penetration and negative patient outcomes 17 - 19 .

Current therapies concerning anti-angiogenesis include the use of organic and synthetic molecules such as pazopanib, regorafenib, and lenvatinib as mentioned in recent research 20 . However, repetitive reports show complicated resistance mechanisms to these drugs resulting from interactions between bone marrow stem cells, tumor cells, and local differentiated cells that give rise to tumor escape from antiangiogenic drugs 21 . Combining advanced nano-delivery systems with antiangiogenic drugs will less likely stimulate interstitial fluid pressure, provide more oxygenation inside the tumor microenvironment and further restrict drug resistance mechanisms 22 .

Biochemical and metabolic alterations in cancer cells lead to enzymatic functional abnormalities, apoptosis induction, and altering extracellular/ intracellular transport pathways, all of which lead to molecular processes associated with drug tolerance. Perhaps the most important example is the upregulation of MDR-related protein pumps, often recognized as P-glycoprotein, an ATP binding cassette transmitter that is qualified to extrude many chemotherapy agents through cell membranes, thus decreasing drug-target association 23 . Furthermore, due to the non-specific systemic bioavailability, the complete clinical advantage of certain therapeutic agents is impaired, resulting in systematic cytotoxic effects and reduced concentration of needed drugs specifically for tumors. In parallel with this, a recent analysis focuses on the development of more selective regional drug dissemination or drug-targeted intervention to address these barriers. In other words, current therapies require high-dose tumor chemotherapy drugs with minimal risk to healthy neighborhoods 24 , 25 . There are instances of monoclonal antibody-grafted medications that attach to molecular objectives mainly overexpressed across cancerous cells 26 , 27 . It, therefore, makes it easier to target drugs directly to the tumor while at the same time minimizing their distribution to healthy cells which will not strongly bind to the antibody. Experiments, however, have shown that only 1 to 10 parts per 100,000 monoclonal antibodies injected intravenously meet their parenchymal objectives in vivo, with comparable drawbacks for molecular diagnostic agents. The use of nanostructures for the release of therapeutic drugs, the treatment of tumors, and the follow-up of tumors using multiple imaging techniques is a recently evolving strategy to address these concerns 26 , 28 , 29 .

Unparalleled developments in the field of nanomedicine have taken place over the last few years, with the development of modern nanostructures for detection as well as therapeutic interventions for disorders such as cancer 30 . Despite their limited scale, nanomaterials have special physicochemical functions that cause nanostructures to have a surface-to-volume relationship that is also greater than most nanomaterials themselves. Thanks to its extensive usable surface area, some molecules, including tiny molecule medicines, probes, RNA, DNA, and proteins, can be attached, absorbed, and transported by nanostructures. Their controllable scale, surface, and configuration features further qualify nanomaterials to provide excellent durability, extreme volume, built-in functionality of hydrophilic and hydrophobic materials, and versatility with numerous routes of administration. The latter makes them extremely desirable in many areas of medical sciences (Figure ​ (Figure2) 2 ) 31 , 32 . While their physicochemical characteristics can be determined mainly during their design (e.g. shape and size) as well as the material from which nanostructures are produced, nanomaterials are generally reasonably durable across broad pH and temperature ranges. On the contrary, the absence of biodecomposition and also the slower release levels in some nanostructures raise alarms about their safety and health concerns, particularly during their prolonged implementation. Still, some nanostructures (e.g. lipids, phospholipids, chitosan, and dextran) may be classified as biological substances 33 , 34 , like carbon-based compounds (e.g. carbon nanotubes) 35 , while, there are inorganic nanostructures (e.g. metal oxides, metal-based compounds, and metal sulfides) 36 , 37 which further involve semiconductor nanostructures (e.g. quantum dots (QDs)) 38 With unique interactions with cells, based on their structure (Figure ​ (Figure2) 2 ) 32 , 39 , 40 .

Main Features of Nanoparticles. Different choices available to design a nanostructure based on what method is used to apply the nanomaterial in cancer therapy. Different surface coatings of nanoparticles (left side), different materials available to design nanoparticles (right side), and some of their general properties are shown. Created with BioRender.com.

This research explains how nanostructures can be employed in chemotherapeutic drug delivery systems to enhance their therapeutic efficacy; how they would be used as therapeutic drugs for thermal photodynamics and gene therapy; and how nanomaterials can be used as molecular diagnostic carriers to identify and track cancer development.

Nanostructures as carriers for drug molecules

The transmission of medications is one of the main fields in which nanotechnology continues to fundamentally change the cancer treatment process. Two primary aspects of nanostructures are currently evolving: nanostructure on its own being used as both carrier, and chemotherapeutic medicine 41 . Second, The medication may either be absorbed into the body directly, or dissolved within the nanoparticle framework, becoming covalently bound to the surface of the nanostructure 42 .

The investigation used by paclitaxel has shown that the formulation of drugs in form of nanostructures prolongs both its level of cytotoxic activity throughout cultured cells and its therapeutic efficacy in living animal models, as opposed to the traditional use of drugs 43 , 44 . This was due to higher biocompatibility, as well as the prolonged bioavailability of nanoparticles, which aids the drug dose to maintain above the required effective value over longer periods. Furthermore, the design of nanoparticles overcomes the problems associated with the re-implementation of paclitaxel including poor water solubility in media and extreme adverse effects associated with the Cremophor EL adjuvant 45 , 46 .

The following criteria for nanomaterial-drug systems must be met to effectively transfer their loads directly to cancerous cells inside organisms:

• To ensure the systematic distribution of drugs, the structure of the nanoparticle drug must remain constant throughout the serum.
• It is necessary to distribute the nanoparticle-drug matrix to tumor cells (either through enhanced permeability and retention (EPR) or through receptor-mediated interactions), thus reducing any unintended problems caused by non-targeted transmission.
• Nanostructures must have the potential to release drugs once they are located in the tumor.
• To ensure safe degradation, the remaining nanostructure carriers should preferably be constructed of a short-lived or biologically inert substance.

If, on the other hand, a non-biodegradable material is used, it must have been proved to be harmless at required levels or to be free from the source material 47 - 49 .

The complex of nanomaterial-medication

Nanostructures used as vectors will also bind to the medicine or encapsulate the medication to prevent both breakdown and denaturation 49 . Nanostructured materials carriers often provide the ability for hybrid treatment defined as the co-delivery of two or more drugs simultaneously 50 . New uses often require the transmission of non-cytotoxic prodrugs that can become functional after administration to cancer cells (e.g. platinum-centered chemotherapeutic substances [Pt]) and can be photo-reduced from their prodrug form Pt[IV] to functional Pt[II] antitumor agents when transmitted through visible light within cells using nanostructures 51 . There are many forms of nanostructures, namely solid lipid, liposomal, polymer-based, inorganic, and mesoporous silica nanomaterials used as carriers. Liposomes are biologically oriented nanostructures consisting primarily of amphipathic phospholipids enveloping an internal aqueous region formed by concentric self-assembly of a lipid bilayer (Figure ​ (Figure2) 2 ) 52 , 53 .

They are capable of storing hydrophilic drugs and maintaining an inner aqueous framework and therefore, are able to be configured for attachment to cell membranes during endocytosis and to continuously release medications. Research has shown improved pharmacokinetics and pharmacodynamics of liposome-related products. Liposomes have been surface-operated with polyethylene glycol (PEG) and glycolipids to inhibit their accelerated removal from systemic circulation through reticuloendothelial system phagocytic activity 54 , 55 . The introduction of PEG or other water-soluble conjugates on the outer surface of all types of nanostructured vectors, such as liposomes, improves the biological fluid stability of the nanostructure while at the same time producing a dynamic network of hydrophilic and neutral surface chains that reduces protein opsonization and enables nanomaterials to potentially escape RES macrophages (Figure ​ (Figure2) 2 ) 56 , 57 . This will improve the half-life of nanoparticles across the bloodstream, which, together with their ability to graft targets, will allow them to selectively concentrate at the tumor site. Although liposomes were initially thought to penetrate cells by merging their phospholipid membrane with cell membranes, the explanation for this mechanism is now assumed to be endocytosis (Figure ​ (Figure4 4 ) 58 , 59 . The medicinal effects of chemotherapy-filled liposomes, such as doxorubicin and daunorubicin, for the treatment of patients with hematological malignancies and solid tumors, are being studied in ongoing clinical trials 60 , 61 . Doxil refers to a PEG-decorated liposome filled with doxorubicin, which has been shown to improve pharmacokinetic properties as well as to decrease serious side effects compared to similar medications and doxorubicin alone. It has been authorized by the FDA to treat patients with metastatic breast and ovary as well as human immune patients with Kaposi sarcoma 62 , 63 .

Drug loading, cellular delivery, and release through liposome nanoparticles (left side. Also methods to prolonge the bioavailability and increase target specificity in liposome-based nanostructures are shown (right side). Created with BioRender.com

Solid lipid nanoparticles (SLNs) were advanced in the 1990s as a superseded carrier structure for liposomes, emulsions, and polymer-based nanostructures 64 . Due to their robust hydrophobic lipid core enclosed by monolayer phospholipids, they are much more durable than liposomes throughout biological processes (Figure ​ (Figure4 4 ) 65 . In these payload architectures, the benefits of colloidal lipid emulsions are often incorporated into solid particulates. Because they are often environmentally friendly, they become less hazardous than mesoporous silica or polymeric nanomaterials 66 . SLNs made up of 0.1-30% lipid matrix spread throughout the watery solution and remain stable at 0.5-5 percent of the surfactant when required 67 , 68 . Since it is straightforward to control the variables included in the SLN synthesis, the SLNs are being constructed using the following: 1) a drug-filled casing, 2) a drug-filled center, and 3) a uniform composition, with a specific release of drugs by each model 69 , 70 . Since drugs have often been seen at lower temperatures to penetrate the SLN whereas, to escape it at higher temperatures, methods of induction of hyperthermia may be used to charge and discharge SLNs with medicinal products 71 . A strongly organized crystal lattice does not handle large amounts of medication as integrated drugs are placed inside lipid layers, fatty acid chains, or inside crystal imperfections. Increased loading of drug1 is therefore feasible when using more specific lipids (e.g. monoglycerides, diglycerides, triglycerides, or separate chain lengths) 72 . Even so, for the lipid matrix, the drug loading potential of traditional SLNs is reduced to around 25%. Temperature changes can often contribute to polymorphic transformations during storage or delivery, which may cause the substance to be expelled prematurely from the lipid network (Figure ​ (Figure3) 3 ) 73 . To address these issues, besides increasing the payload of drugs and prohibiting the elimination of drugs, SLN variants have also been generated 74 .

Different assembly methods for Nanoscale delivery of small molecules. The capacity of each nanostructure to encapsulate drug molecules is shown. Created with BioRender.com

Although most nanostructures are based on polymers, in general, nanospheres and nanocapsules, are labels applied to any form of polymer nanoparticle 75 . While nanospheres typically become globular or rigid by substances bound to their exterior side, nanocapsules remain vesicular structures containing compounds enclosed inside a cavity with a solid shell covered by a liquid kernel (either oil or water) 76 . Polymer nanostructures may be manufactured through classical polymerization or polymeric reactions of constructed polymeric materials. The chemistry included in nanomaterial production may be effectively modified to allow them to attain desirable characteristics such as surface functionalization which itself, improves the characteristics of biodistribution and pharmacokinetic regulation. Research also indicated that the degree and magnitude of the release profile of nanomaterials can be precisely adjusted in relation to the volume of nanostructure absorbed into cells by specifically controlling the drug-to-polymer ratio as well as the polymeric structure and molecular mass 31 , 40 , 77 . For example, polylactic acid (PLA), poly(e-caprolactone), poly(lactide-coglycolide) (PLGA), polyglycolic acid and polyglycolic acid are biodegradable synthetic polymeric nanostructures (alkyl-cyanoacrylate) 78 - 80 .

Natural polymer compound examples include gelatin, dextran ester, and chitosan. Although they may only have adequate purity-related effectiveness or reproducibility relative to synthetic polymeric materials 81 . Over the past several decades, polymer-based nanostructures have also been researched for drug delivery applications. For instance, the FDA accepts environmentally friendly polymer-based nanostructures like PLGA and PLA for human use 78 , 82 . The application for paclitaxel attached to the organic polymer-based albumin nanostructure for the medical treatment of patients with metastatic breast cancer has also been approved by the FDA, while the polymer-based nanomaterial composition containing docetaxel is currently in the initial phase of clinical studies for patients with progressive solid malignancy 83 .

Mesoporous silica nanomaterials have also been extensively researched to evaluate their capability to maintain the drug bioavailability and prevent denaturation or degeneration of drug molecules due to their property in providing physical encasement. Mesoporous nanostructured surface openings could either contribute to a centralized container filled with a drug product and dynamic worms could shape nanomaterials themselves - like a channel system that allows a relatively large quantity of drugs to be distributed in a regulated manner. The distribution of pore sizes has also been shown to be helpful to evaluate the pharmacokinetic profile of the drug payload 84 , 85 . The investigation also evaluated the reversible coating of mesoporous silica nanomaterial outer side openings that mechanically minimized the unleash of medications until nanomaterials reached their zero early release target. Cadmium sulfide, by which disulfide-containing organs are chemically clearable by disulfide-reducing substances or nano-based iron oxide nanostructures is also investigated. Membrane-impermeable drugs may be distributed through such cargo structures, acting as an intracellular drug transporter and a tool for image processing operations 86 , 87 .

A wide variety of nanomaterial systems are made up of inorganic nanoparticles; metals, metal sulfides, and metal oxides. They are capable of being developed in form of prototypes with excellent reproducibility, varying in scale, shape, and pore size, and can be conveniently coupled with tumor-targeting ligands and chemotherapy drugs. Furthermore, in order to generate nanomaterials that can escape the RES, their surface structure can often be effectively modified 88 . They are fairly constant over wide ranges of temperature and pH, especially in comparison to liposomes and nanostructured solid lipid carriers (Figure ​ (Figure2). 2 ). However, their inadequacy of biodecomposition and their relatively low rate of degradation give rise to doubts about their post-delivery removal 89 , 90 .

The nanomaterial- medication complex's durability

The level of renal excretion or reticuloendothelial system (RES) activity affects the circulation of the blood throughout the kidney. Comparatively small nanomaterials are easily removed by the kidneys, while larger nanostructures are removed by RES. Nanomaterial capture of RES cells reduces their systematic bioavailability. Surface functionalization with water-soluble PEG chains will, however, offer "stealth-like" properties to nanostructures, culminating in their continuous presence throughout the bloodstream by decreasing the immune responses against them as well as preventing their detection and phagocytosis through the mononuclear phagocytic renal system 91 , 92 .

Besides, PEGylation seems to be necessary as "bare" nanomaterials, adsorbs proteins that allow them to accumulate in biological systems. This prohibits the solution accumulation of nanoparticles and the formation of clusters while entering the vascular system where they potentially embolize vessels and block the supply of blood to remote locations and organ systems leading to microinfarction 93 , 94 .

Tumor cell delivery of the nanoparticle-drug matrix

Nanomaterials may be delivered to tumors either passively or actively after introducing to the circulatory system. Nanostructures can benefit from the specific effect of EPR in tumors through passive transmission, which allows them to escape the bloodstream and reach the extravascular area where they localize close to solid tumors. Nanostructures should preferably be thinner than 100 nanometers to maximize their efficacy. Due to the variability in the bloodstream supply of a tumor mass, as well as bio-physiological limitations, and in some cases stiffness of the intercellular framework, the location of nanostructures within the tumor would not be consistent 95 . Instead, using surface functionalization, nanomaterials can effectively target tumors (e.g. binding of ligands including small molecules, peptides, oligosaccharides) 96 . An antigen or receptor may be the target substance, but it must strictly express over the malignant cells and express at close to zero or marginal thresholds for healthy cells. Nanomaterials are competent to improve the transfer of drugs by targeting tumor cells directly, while also helping to reduce the toxic effects of the free medicine on non-target tissues. thus, enhancing the quality of cancer treatment. The assessment has already shown that the attachment to multiple receptors at the same time contributes to the multivalent properties of nanostructures enhancing the ability to interact with cancer cell membranes 97 .

Examples include nanostructures attached to folate ligands that have a tenfold higher sensitivity to folate binding protein than free folate since folate receptors are also located on the surface of cancer cells in clusters. Besides, PEG chains attached to nanomaterials may also be functionalized by binding to tumor-specific conduits to enhance their bioavailability 98 , 99 .

Drug release from the nanomaterial-medicine framework

The nanomaterial-medication matrix should be broken after it has been delivered to the tumor site to activate the medication 100 .

Medications become free from nanostructures when attached to cancer cells either by leaking out of the frame or by swelling, erosion, and breakdown of nanomaterials. An innovative photo-engineered nanomaterials vehicle, for example, has recently been established that initiates a reversible shift in diameter when ultraviolet light is applied that facilitates the diffusion of therapeutic agents, thereby providing spatial and temporal drug release management 101 . However, the therapeutic implementation of this current technique may be severely hindered by insufficient absorption of ultraviolet radiation into the tissues. Additional systems are required for the desired features of hybrid nanostructures that enable a multi-stage delivery method. Thus, each of the different layers of the nanostructure reacts separately to the surrounding physiological systems in such a way that variations in pH, oxidative stress, or temperature (e.g. in the acid microenvironment of the tumor) can lead to variations in the structure of the nanostructure causing the release of pre-loaded therapeutic agents (Figure ​ (Figure5) 5 ) 102 , 103 . This change in diameter is caused by proteases primarily expressed in the microenvironment of the tumor. For example, the metalloproteinase-2 matrix deforms the nano properties of 100 nm gelatin 104 .

Removal of the main cancer cells. Cancer stem cell-specific markers serve as important drug targets for active targeting by nanoparticle-drug systems. Following the target-specific attachment of the nanostructure, drug release can be achieved using internal or external stimuli. Different choices for drug delivery and release are demonstrated in this picture. Created with BioRender.com

These properties are effective in the treatment of tumors that produce fibrillary collagen type I and type III throughout interstitial spaces. The latter thickens the extracellular matrix and causes fibrosis, impairing further spread and absorption of larger nanostructures 105 , 106 . The capacity of nanostructures that enable the controlled release of medications through their framework often resolves the challenges of drug release at fixed speeds regardless of the needs of the patient and the ever-changing tumor environment. The mechanism by which the drug release can be controlled allows the concentration of drugs to be maintained over a long period throughout their therapeutic window and also enables the use of multiple doses for a single treatment 107 . It was also proposed to help facilitate 'chrono-administration' of the drug 101 , in which it was speculated that the precise timing of the distribution of therapeutic agents was crucial in ensuring optimum therapeutic impact in order to optimize tumor destruction and reduce metastatic spread. When released from the nanomaterials, the next obstacle for most chemotherapy agents is now to spread within cancer cells to affect targeted substances in intracellular media. It is difficult to see how quickly medications can penetrate the cellular environment, either through activated delivery processes or through receptor-facilitated endocytosis mechanisms, and how limited their distribution is in the proximity of cancer tissues 108 . Some researchers are therefore designing techniques whereby the whole drug-nanoparticle structure may penetrate cancer cells before the actual release of pharmacological drugs into the cytosol to improve the accuracy of drug distribution to appropriate intracellular targets 108 , 109 . They are working to promote intracellular absorption by marking nanomaterials with peptides to penetrate the cells, like Penetration and anti-actin-targeting substances such as transcription transactivator (TAT) peptide in accompanying with a nice arrow peptide 110 , 111 . As most of the mentioned compounds have main objectives inside the cells, they are anticipated to have a stronger therapeutic impact. In addition, this is particularly advantageous for medications that are often quickly ejected by cells utilizing membrane transporters, including protein-based pumps correlated with multidrug resistance, and it is shown that P-glycoprotein often acts by detecting drugs that need to be expelled outside the cells, especially when they are found inside cell membranes 112 . The chemical composition of the nanostructure will contribute to the release of drugs once they reach inside the cell. For example, when medicines are grafted with nanomaterials through thiol groups, these nanostructures can be replaced with glutathione, which remains widely available throughout the cytosol, leading to the unleashing of almost any trapped medication 113 . In situations where the nanomaterial-medication framework is not directly absorbed or internalized into cancer cells as a whole, the drug could now be transported out of the cell, apart from the nanostructure, where it could then reach the cell through direct diffusion and possibly other transport mechanisms 91 . The downside of this drug distribution system is that a large amount of the drug will be redistributed to the natural tissues around it, thus reducing its efficacy in the treatment. Furthermore, since the interstitial atmosphere surrounding the tumor is acidic, it, therefore, produces a hazardous microenvironment for the transmission of medicines that decreases the efficacy of alkaline chemotherapy drugs.

Elimination of the remaining nanostructure after release

Most of the nanoparticle drug structures produced has been made up of environmentally friendly substances (e.g. lipids, phospholipids, chitosan, and dextran) which allow the drug to be released once the nanomaterial container has been degraded 114 , 115 . Non-biological vectors are therefore reasonably stable through high pH and temperatures, and the latter include inorganic nanostructured materials. But this is of major concern for their lack of post-drug release transmission, biodecomposition, and biodegradation 39 , 116 . Therefore, whenever these non-biological products are used, they must be properly eliminated from the body's environment or maintained in a stable state within the body's environment (e.g, in dysfunctional macrophage cells). Nanoplatforms may also be designed to closely monitor the chemistry of nanostructures through which, nanomaterials may disintegrate into their specific building fragments, which are not expected to be hazardous following drug transmission 116 .

Nanostructure as a therapeutic substance

Photodynamic treatment.

Photodynamic therapy (PDT) across cancer services has increasingly become a powerful therapeutic alternative. PDT uses a photosensitizer that is recognized as a light-activating molecule that absorbs light from certain wavelengths in order to produce molecular species that are dependent on cytotoxic oxygen. Such sensitive chemical species are responsible for the destruction of subcellular organelles and also cell membranes, which consequently induce apoptosis, necrosis, or autophagia, in other words, cell death 117 . The energy obtained from light can lead to free oxygen radicals' production from superoxide, hydrogen peroxide, and hydroxyl radicals with molecular oxygen 118 . The efficacy of PDT depends to a large extent on the degree to which photosensitizers can induce singlet oxygen generation, as well as on their ability to deliver it specifically to the target tumor tissue at therapeutic concentrations. Since single oxygen-based products have a limited lifespan of fewer than 3.5 microseconds and can only be distributed between 0.01 and 0.02 lm, their degree of disruption or damage is limited to the concentration of photosensitizing substances typically found in the endoplasmic reticulum or mitochondria 119 . Since some photosensitizers capture light below 700 nm across the visible spectrum, light penetration is minimized to only a few millimeters, allowing only relatively superficial lesions to be treated 120 . However, developments in optical engineering have made it possible to create optical fibers that can be inserted into endoscopes, bronchoscopes, and colonoscopes in order to facilitate the transmission of light to the inner body cavities, thus increasing the range of PDT 121 . PDT is currently being studied in the treatment of many tumors such as bladder, skin, lung, prostate, pancreatic, esophageal, and stomach tumors 122 , 123 .

It is theoretically possible to identify the nanostructures used in PDT as active or passive 124 . PDT nanomaterials in a passive manner photosensitize vectors and can be manufactured either from environmentally friendly or non-polymeric components like ceramic and metal nanostructures 125 .

Due to their potential to include large carrier photosensitizers, it has been demonstrated that biodegradable nanostructure containers consisting of PLA or PLGA are a substitute for liposomes 126 . This is critical as photosensitizers with inherently low water solubility are highly hydrophobic and culminate in the solution aggregation that reduces the possibility to control them. The morphological features of the polymeric matrix may also be ideal for the controlled deterioration of the polymer content and therefore good for triggering the release of the photosensitizer compound 127 . Photosensitizer-loaded nanomaterials have been shown to have more photoactivity than "free" photosensitizers 128 . In addition, due to their increased level of intracellular absorption through endocytosis, smaller nanocarriers have significantly higher phototoxic effects compared to relatively large nanovectors, triggering the release of photosensitizers inside the cytoplasm but not in the extracellular environment 117 . Moreover, the narrower the scale of the nanostructure is, the higher the surface-to-volume ratio will be which increases the surface area that is accessible to the ambient environment, leading to higher levels of photosensitizer release 129 . Photosensitizers may be filled with non-biodegradable and non-compostable substances and may also be more beneficial to be filled with organic polymer-based nanostructures regarding better durability; regulation of pore size, volume, pH tolerance, and mitigating microbial hazards. In addition, specific targeting of tumor tissue may be quickly achieved, allowing accurate agglomeration across the cancer target of photosensitizers, thus reducing the concentration of photosensitizers throughout healthy non-target body tissues. This will therefore reduce any amount of light-sensitive substances required to produce a comparable optical toxicity effect and thus increase the capacity of phototherapy. Low irradiance can be utalized to convert the significantly higher emission energy by employing two-photon absorbing dyes, so that single-oxygen radicals can be directly generated from the oxygen-driven molecule. The benefit of the entire mechanism is that light beam is allowed into deeper tissues within a clear tissue gap (from 750 to 1000 nm). However, the toxicity of the dye remains a major concern. The dye entrapment into a biologically inert nanomaterial container will also help reduce its toxic effect on healthy tissues, allowing PDT to penetrate deeper body tissues and organs. Several other researchers have also investigated the potential use of light-sensitive substances with exciting properties (receptors capable of having energy) that gain fluorescence resonance energy from photon-absorbing dyes called energy donors 130 . This method provides an effective energy transfer between the intermediate dye and the activated encapsulated photosensitizer through the physical embodiment of the dye as well as the photosensitizer within the same nanostructure. In this method, the load-bearing strength of the dyes capable of absorbing photons must be significantly greater than those photosensitizers capable of accepting energy for a successful photon excitation. Since functionalized silica nanomaterials are biocompatible, durable with no releasing embedded hydrophobic compounds and ideal for PDT, they have therefore gained importance as their porous framework becomes permeable to oxygen molecules 131 , 132 .

Without a photosensitizer, active PDT nanostructures can produce free radicals and reactive species themselves. This was initially understood by Samia et al, who discovered that the semiconductor QDs were capable of producing singlet oxygen individually using the transfer of energy from the triplet state without photosensitive materials despite a poorer specification, to have access to photosensitive substances through the transfer of fluorescence-based resonance energy 133 In order to contribute to the enclosure of photosensitive substances and directing these substances towards cancer cells, other researchers have shown the potential of nanomaterials to play an extremely effective intermediate role through the PDT method 134 . During radiation with x-rays, such nanostructures can release luminance with an adequate wavelength to functionalize photosensitizers, bringing treatment to locations deep inside a tissue that is usually hardly exposed to radiation. Comparatively, converting nanostructures appears to be effective for absorbing low-energy radioactivity (e.g. NIR irradiance that is capable to penetrate body tissues of approximately a magnitude greater than light waves) or generating more energy-intensive radiance that can also trigger photosensitive substances to generate reactive single oxygen species across the microenvironment 135 , 136 . This is achieved after 2 low-energy photons are captured at the same time, causing nanostructures to move from the basement to the exciting stage using transformation metals or rare-earth ions such as lanthanide. Quantum conversion occurs mechanically, after absorption of the first photon, through a simulated intermediate phase 137 , 138 .

Silencing the gene

Antisense oligonucleotides, plasmid DNA, or small interference RNA (siRNA) are core tools in gene therapy, which is described as a minimum dose gene control 139 . Dicer, i.e. ribonuclease (RNase III endonuclease), forms the siRNA cleavage ability and the clearance of double-stranded RNA. siRNAs are small pieces of double-stranded RNA ranging in length from 20 to 25 nucleotides. In addition to their nucleotide sequence, they can interfere with the translation of unique mRNAs 140 . siRNAs come into contact with a multipurpose protein called Argonaut, the catalytic portion of the mixture of the silencing structure triggered by the RNA 141 . Double siRNA is unscrewed, and Argonaut retards the traveler's RNA strand, allowing the additional mRNA to attach to the residual or anti-sense strand 142 . Subsequently, through its endonuclease operation, Argonaut splits the mRNA, which contributes to the silencing of the expression of the gene, better recognized as RNAi (RNA interference) 143 . This influence may keep on for 3 to 7 days in rapidly dividing cells or for several weeks within cells without dividing properties.

Many molecular targets have been identified to be manipulated in well-characterized pathways that cause cancer. SiRNA, therefore, offers a great deal of optimism that would be sufficient to inhibit not only one gene but so many genomes that contribute to the strong potency of tumor progression and enable several mechanisms to be targeted simultaneously. Positive findings from many in vivo and in vitro RNAi investigations have been obtained in cancer-related mechanisms, such as cell cycle control, tumor-host interactions, and cell senescence 144 . However, many drawbacks are shown by Miele et al, which further limit the efficacy of siRNA in therapy, such as A) transmission difficulties, B) adverse consequences associated with non-objective activities (i.e. a sectional combination of siRNA with a complementary sequence of unintentional mRNA transcription factors) and C) disruption of the cellular machinery of physiological roles 145 .

As released into the circulatory system, unfunctionalized siRNA compounds are extremely reactive and described as limited half-life attributed to serum A-type RNase nucleases and accelerated renal removal. In addition, due to the massive and intense charges of polyanions on the backbone of the phosphate group, non-functional siRNA complexes are unlikely to penetrate the cells, leading to electrostatic repulsive forces from large negative anion charges on the outer surface of the cell membrane. Although it has been shown that chemical functionalization of siRNA enhances intravascular stability and restricts the body's innate immune response without serious impairment of RNAi function, alternative patterns of diffusion involved with nanomaterials, have recently been explored to find additional forms of safe transfer of siRNA 146 , 147 . Nanostructures provide a highly specific surface area and therefore have a large exterior surface compared to their small dimensions for transporting siRNA. Nanostructures can preserve and secure siRNA during intravenous infusion 148 . This contributes to the specific targeted and packed delivery of siRNA to cancer cells after surface modification with tissue-specific ligands.

Nanomaterials are effectively absorbed into the cells, typically through receptor-mediated endocytosis also known as membrane fusion 149 . While inside the target cells, they reach the intracellular transport system, through which the siRNA must be limited until the lysosomal system reduces the RNA 150 . Some of the molecular tools which are used to enhance endosomal evasion include fusogenic proteins and lipids, pH-sensitive polyplexes/lipoplexes, and photosensitive compounds 151 .

Nanoliposomes are potentially the nearest clinical definition of all siRNA-nanoparticle delivery strategies being developed. Nanoliposomes were primarily constructed from organic matter comprised of a phospholipid bilayer and an aqueous center capable of binding to the siRNA. This is achieved by employing electrostatic interactions-stabilized frameworks 152 , 153 . They are usually inert in charge and about 30 to 40 nm in diameter, allowing the cells to absorb them effectively. Nanoliposomes protect siRNA from endonuclease in the bloodstream although their limited serum half-life and rapid RES (e.g. lung, liver, bone marrow, and spleen) inhibit their use for therapy and require repeated injection 154 . Many groups are already studying the future use of sustained-release polymer mixtures to address this issue 155 , 156 . As they are made from physiological lipids, stable lipid nanostructures are being increasingly studied showing considerable bioavailability and limited biological toxic effects. non-biological synthetic nanostructures, including noble metals and inorganic crystalline structures, have also been investigated as vectors for gene transmission as a result of their improved durability and convenient oligonucleotide functionality 81 , 157 , 158 . The optimum diameter of synthetic nanomaterial transporters tends to be between 5 and 100 nm. Due to accelerated renal removal, nanomaterials are designed to measure less than 5 nm, while those larger than 100 nm are captured by RES (where activated monocytes and macrophages degrade these nanomaterial transporters) 159 . Besides, the add-on mechanism allows particles more than 200 nm to be removed easier than narrower nanostructures. Oishi et al first achieved the integration of siRNA into gold nanomaterials using a layer-by-layer assembly process model to design macromolecular configurations to facilitate the continuous release and delivery of siRNA. Also, new porous-silicon delivery approaches are being implemented as the chemical modulation of both the vehicle surface and the transported medicine is needed 160 .

Another first experimental study was carried out by Davis et al in 2010, in which siRNA was packed into a nanostructure consisting of a linear polymer, based on cyclodextrin (a human transferrin-based protein that enables cancerous cells with surface transferrin receptors), as well as a PEG (that facilitates nanomaterial durability to minimize the expression of the M2 subunit of ribonucleotide reductase). Throughout their clinical development, siRNA-packed and ribonucleotide reductase-targeted nanomaterials were routinely delivered to melanoma-bearing patients who were highly resistant to primary therapy. Patients were treated every 21 days on days 10, 8, 3, and 1 with 30 minutes of intravenous infusion. In a small number of post-treatment patients, tumor biopsies revealed the nanomaterials inside the cytoplasmic compartment with subsequent decreases in both protein levels and mRNA expression of the M2 subunit of ribonucleotide reductase, indicating that systemic delivery of siRNA to humans may generate specific gene suppression through the RNAi process. Little, however, has been understood concerning the pharmacodynamics of the RNAi result which depends on the mixture period of the disassembly of the nanostructure and also on the time the siRNA remains inside the RNAi machinery. The use of siRNA against persistent myeloid leukemia, liver cancer, advanced solid tumors, and neuroblastoma is also being studied in many other early-stage medical investigations 161 .

Photothermal treatment

The application of nanomaterials in combination with heat opens a new window toward the effective treatment of malignant tissues. Hyperthermia is referred to temperatures between 40 and 45°C. In addition to apoptosis, temperatures above 42°C have been shown to cause cancer cells more sensitive to subsequent therapies, such as radiation, while temperatures above 45°C are capable of causing direct tumor cell death (e.g. thermoablation) 162 . Tumor-related hyperthermal therapy involves applying thermal energy to tumors using microwaves, radiofrequency (RF), ultrasound, or magnetic fields to cause irreparable cellular injury through membrane softening/loosing and protein denaturation, eventually leading to fatal tumor cell injury 163 . As this actual impact is much more specific to malignant tissues due to their decreased thermal resistance, thermal therapy is questioned because of injury to the nearby healthy tissue. Photothermal therapy (PTT) seeks to resolve this problem by using photothermal substances to achieve more regulated and specific warming in its target region, thereby limiting thermal destruction throughout the tumor 164 .

We need to provide an improved absorption ratio of light as well as efficient light-to-heat conversion rates for photothermal agents to be advantageous. Natural chromophores that struggle with poor absorption or exogenous colors (e.g. green indocyanine) and are affected by photobleaching are conventional agents 165 . Even so, these troubles have been resolved by the advancement of noble metallic nanostructures (e.g. nanotubes of gold nanospheres, nanotubes, and nanotubes) and carbon nanotubes because they have high absorption in NIR electromagnetic spectrum areas, particularly around 650 to 900 nanometres, due to plasmon surface resonance (SPR) 166 , 167 . It is beneficial because, in this range, the majority of biological tissues exhibit limited absorption of light, making the light easier to penetrate in depth. In general, spherical gold nanostructures have the maximum absorption of SPR throughout the visible portion of the spectrum of approximately 520 nanometres 168 . Gold nanotubes, on the other hand, have two absorbance frequency bands in the trajectory of each rod shape (e.g. longitudinal and transverse axes), with a high peak intensity of almost 520 nm in the transverse plasmon band, as well as a high-frequency longitudinal plasmon band, which can be adjusted across the NIR area on the basis of their length-to-width proportion. this makes these nanotubes appealing for in vivo investigations. In comparison, the maximum SPR absorbance for nanoshells based on the gold element can be adjusted by changing the radius ratio of the thickness-to-core proportion of the shell. Their absorbance ratio is 4 to 5 times higher than that provided by photothermal agents due to the SPR of nanostructures 169 .

Photo-excitation of light-frequency metallic nanomaterials in parallel with the SPR-related absorption band of the nanostructure lead to electron-based gas development, which heats up and generates thermal energy but quickly cools by exchanging energies with the nanostructure crystal structure in about 1 picosecond (ps) 170 . After almost 100 ps s , the crystal structure itself cools by exchanging heat with the surrounding media to induce regional tissue destruction. The heating of gold nanostructures often induces a cavitation bubble around the nanostructure. Actually, the heat-triggered cell breakdown processes mentioned above, in turn, lead to mechanical stress that contributes to long-term cell damage 171 . Surveys have shown that, compared to traditional dyes, nanostructures typically improve light-to-heat transfer, requiring less laser energy to achieve localized cell destruction 172 . Nanomaterials need to be tens to hundreds of nanometers in diameter to improve the efficiency of light-to-heat conversion, but this contributes to their low absorption and aggregation within the RES 173 . Researchers are therefore particularly interested in the application of tiny noble metallic nanostructures which, by self-assembly, escape the RES but accumulate at the tumor site. Loading nanoparticles to tumor cells would improve optical density, resulting in extremely low laser power required to increase the temperature above the threshold of cell destruction 174 . Initially, photosensitizer nanostructures must be concentrated inside the targeted tumor after their intravenous/local administration intended to have effective PTT. This can be achieved by surface modification of nanostructures with specific substances capable of targeting the tumor. Cell culture experiments, for example, have recently shown that gold nanostructures conjugated with anti-epidermal growth factor receptor (anti-EGFR) antibody can directly attach or charge carcinogenic cells representing EGFR to allow PTT to produce high temperature shocks of around 70 °C to 80 °C and consequently, contribute to thermal ablation necrosis of tumors 175 , 176 . By comparison, for cell types that did not have nanomaterial tags, no photothermal destruction was reported while cell death occurred for four times that the thermal energy required for the destruction of cancer cells was provided by gold nanomaterials labeled anti-EGFR. The next step is to transmit light radiation directly to the tumor region, which is typically achieved by using NIR-based laser instruments, eithine fiber optic catheters and endoscopes capable of being mounted close to the tumor. The promising effects of PTT on cultured cells, ex vivo human samples and live experimental animals have shown significant potential for this cancer treatment strategy, either independently or in conjunction with many other therapeutic approaches. Initial clinical experiments with AuroShell nanostructures consisting of a metallic shell of gold and a non-conductive dielectric core are launched for advanced head and neck cancers using NIR-PTT 177 .

Iron oxide nanomaterials within water have also been found to produce thermal energy in presence of an endogenic alternating magnetic field when introduced into tumors 178 . Iron nanostructures provide a high particulate density inside the water (e.g. magnetic fluids), which is responsible for making a large overall outer surface area of the magnetic components, resulting in a remarkable strength of their absorption properties. This makes them a particularly useful tool to reach the uncontacted tumor intracellular environment 179 . Magnetic fluid hyperthermia, on the other hand, has shown positive outcomes for malignant glioma, prostate cancer, and breast cancer (phase 1 clinical trials are currently underway for prostate cancer and phase 2 clinical trials for cerebral tumors) 180 . Hyperthermia based on magnetic fluid, however, cannot currently be achieved by the systematic administration of nanostructures of iron oxides.

Nanostructures as carriers for image processing

Standardized image processing technology employing magnetic resonance imaging (MRI), simple radiographs, computed tomography (CT), and ultrasound are commonly utilized for both cancer-related monitoring and subsequent intervention 181 . Such techniques, however, depend on the detection of cancer until they represent a recognizable activity at about 1 cm, where the tumor volume is already close to 1 billion cancer cells. Conceptual changes have also taken place over the last few years, from anatomical image processing, which recognizes macroscopic/gross pathology, to molecular diagnostic images, which facilitate the diagnosis of cancer on a molecular scale even before phenotypic shifts occur 182 . Molecular diagnosis enables the in vivo characterization of the genetic alterations that occur in oncogenesis, thus determining the method of molecular treatment highly advantageous to the patient population (e.g. personalized medicine) 183 , 184 . It also facilitates continuous non-destructive monitoring of the response, development, and transformation of the condition during treatment or relapse. Conventional imaging techniques have the potential to use imaging compounds to demonstrate current characteristics, (e.g. blood vessels and tissue perfusion after intravenous injection of a contrast agent). Tiny molecules of approximately 2,000 daltons or 1 nm were conventionally used as imaging factors (e.g. iodinated small molecules for CT, 2-deoxy-2-(18F)fluoro-D-glucose (FDG) for positron emission tomography (PET), and chelated gadolinium for MRI) in clinical settings 185 , 186 . However, the development of modern probes resulted in poor signal strength, weak durability, non-specificity, and accelerated removal from the circulatory system. By addressing these drawbacks, nanostructures have shown considerable potential and are therefore actively used as molecular diagnostics. Nanostructures, for example, can improve signal strength when using optical imaging techniques, allowing lower cellular communities to be visualized at higher tissue depths, and also producing imaging signatures that are persistent over long periods 187 .

Since nanoparticles can be covered with several types of ligands, they also have strong affinity and specificity that allow for binding interactions with target cell groups that increase their persistent affiliation by 4 to 5 magnitude orders 188 . It is beneficial since more nanostructures are concentrated at the precise location of the tumor, thus increasing the signal-to-noise ratio and making it easier to properly illuminate cancerous tissues compared to the nearby healthy tissue. The bulk of nano-sized imaging substances are often greater than 10 nm and are therefore not normally removed from the circulatory system by the kidneys; this assists them to have prolonged circulation periods relative to smaller particles (i.e. minutes vs. days) 31 , 189 . This is beneficial as it facilitates repetitive image analysis without the need for more nanoparticles to be administered.

Experiments have also shown that narrower nanostructures have more homogeneous tissue bio-distribution compared to spherical nanomaterials and non-spherical nanomaterials (e.g. nanotubes, nanodisks, nanoworms, etc.) being more effectively distributed to target tissues 190 . In addition, they must be balanced against unexpected non-sphere-related toxic effects. Because cancer is rarely detected by a single molecular-based approach, the sensitivity of clinical diagnosis can be improved by identifying several molecular targets that are up-regulated while oncogenesis is present (e.g., a process known as multiplexing) 191 , 192 . One way to do this is to label multiple nanomaterials, each against a specific aspect of a molecular biomarker, and then deliver all of these nanomaterials simultaneously 193 . Signals identified from multiple nanomaterials attached to cancer cells can then be decoded to allow therapists to evaluate the molecular fingerprint of tumors. This would make it possible, in particular, for the patient to be provided with scheduled molecularly targeted treatment. If the molecular signature of the cancer is already understood, an alternative approach is to mark a single nanostructure with many separate ligands, each of which to be directed to different molecular targets and recognized as over-regulated in tumors under examination 194 . Compared to the background tissue, the tumor may have many of these targets thus, more nanomaterials can be attached and bring a larger signal. Nanostructures can eventually be constructed to be multidimensional so that two or more separate imaging techniques (e.g. MRI and fluorescence) can be applied for visualization of the tumor 195 . Several researchers are also actively exploring strategies for the separate administration of sub-components of nanostructures to improve the efficiency of the transmission of nano-sized imaging substances to the location of the tumor mass. Such subcomponents can also be self-assembled in presence of stimuli, such as pH fall, adaptation, or enzyme cleavage, to create a supramolecular nanostructure probe that can eventually be used for image processing 196 - 198 . The value of this technique is that these specific sub-components are narrower and more penetrative to the tumor to confirm aggregation only at the specified location. An example can be monomers (containing gadolinium bind 2-cyanobenzothiazole and 1,2-aminothiole) and protease-sensitive motive probes(like caspase-3 and furin,) that are over-expressed across tumor cells 199 .

Superparamagnetic iron oxide nanoparticles (SPIONs) are currently used in wide medical applications including cardiovascular disease, hepatic injury, lymphatic system, and cell imaging. Still, several pre-clinical investigations are already underway to develop different nanoscale therapies 200 , 201 . Iron oxide (maghemite, Fe 2 O 3 ; magnetite, Fe 3 O 4 ) nanomaterials, if their central dimension is 20 nm and smaller, become superparamagnetic at the ambient temperature, allowing around micromolar levels to adjust T 2 relaxation periods and water-related protons to improve the contrast in MRI images 202 . In vivo , SPIONs are often known to have minimal toxic effects as they are assumed to be environmentally friendly; With nanomaterial iron breakdown and its further release into the normal plasma iron stream, it will eventually become integrated into erythrocyte hemoglobin and used for other metabolic pathways 203 , 204 . Although SPIONs are phagocytized by RES cells, they have been used to diagnose liver lesions. Since healthy liver parenchyma produces RES, SPIONs may accumulate and weaken the signal strength for both T 1 and T 2 photos. Many liver tumors, on the other hand, restrict producing RES and therefore refuse to absorb SPIONs that increase the differentiated contrast between the mass of the tumor (large signal pulses) and the adjacent tissue (poor signal pattern) 205 . Furthermore, since SPIONs are paired with ligands for successful targeting, these signal properties are reversed. SPIONs can now be collected at the location of the tumor under these conditions, resulting in weak signaling relative to baseline liver parenchyma; this also depends on SPIONs that restrict RES 206 . Polymeric materials typically SPIONs are used in targeted delivery to inhibit RES and promote colloidal durability and cytocompatibility (i.e., starch, dextran, or PEG) 40 , 207 . As a result, ligand molecules like folate are grafted onto SPIONs by their polymer coating materials,(either PEG or dextran) 208 . Folate is used as a ligand molecule because folate receptors are usually up-regulated/highly expressed on the apical surface of cells during the cell proliferation of malignant tumors due to the essential role of folate in cancer while these receptors are present on the outer surface of epithelial cells in limited quantities. 209 . Transferrin molecule also strongly bounds to SPIONs when attached to the transferrin receptor (generally referred to as CD71), a type II transmembrane glycoprotein that is differentiated and highly expressed across the proliferating surfaces of cancer cells due to its elevated iron requirements 209 , 210 . SPIONs have also been integrated into different sequences of peptides, including arginylglycyl-aspartic acid (RGD), and may combine with integrins such as avb3 expressed on proliferating endothelial plasma membranes (including those experiencing angiogenesis) 211 . Initially, the diagnosis of disease in vivo was not looking feasible by SPIONs functionalized with monoclonal antibodies due to the large particulate diameter that allowed its accelerated removal by RES. Even so, with some experiments suggesting monoclonal antibody-conjugated SPIONs have a high affinity to antigen-expressing tissues, this has proved not to be the case 212 . In laboratory animals, EGFR antibodies were integrated with SPIONs to detect small lung cells, esophageal squamous cells, and colorectal carcinomas 213 - 217 . However, it dramatically enhanced the scale of the nanoparticle-antibody conjugation system, and a decrease in stealth-like functionality was observed. Some classes are “ already grafted SPIONs to aptamers ”, which are synthetic rather small selected sequences of oligonucleotides that can bind to ligands with extreme affinity and specificity. Double-modality probes such as dextran-coated 64 Cu-SPIONs are now being produced, while clinicians are planning to implement them for dual-mode MRI/PET image processing in the immediate future. Throughout clinical settings, optical imaging has never achieved its maximum capacity and, in most cases, appears to be a preclinical/research imaging technique 218 .

Fluorescent has traditionally been used for optical imaging. In vivo uses of fluorescence are restricted by 1) the minimal amount of fluorescent-based imaging substances accessible only throughout the NIR range, thus preventing the use of low-power laser beams for sampling; 2) the potential background autofluorescence in superficial body tissues, thus limiting the depth or intensity of such imaging; 3) broad spectrum overlap between fluorescent-based imaging substances, preventing different targets from being detected at the same time; and 4) accelerated photobleaching of fluorescent-based substances that limits the length of the investigation 218 - 220 .

QDs, as a modern type of nanomaterials, are used for optical image analysis. An example is nanocrystalline semiconductor materials, usually made of metallic materials such as zinc or cadmium from sulfides or selenides, which vary in diameter between 2 and 10 nanometers 221 - 223 . The wavelength ranges of the radiation generated do not depend on the QD components, but rather on the structural aspects of the QDs. Thus, the ability to track or adjust the QD dimension properly determines the wavelength, and the coloring of the reflected light. The latter is commonly referred to as the "size quantization effect" 224 . Regarding the interpretation of the light emitted through human beings, the emission pattern of the QD can therefore be configured purposed to provide peaks corresponding to the wavelength range right across the continuum of light waves, regardless of the frequency of excitation. QDs are therefore found to be approximately 20-fold brighter as well as 100-fold more durable than conventional fluorescent reporters (e.g. less sensitive to photobleaching), allowing them to also provide better tissue penetration while becoming more functional for lengthy image processing. QDs are included in a wide range of applications in biological sciences at the molecular level to date. This involves DNA recognition, cell sorting, cell monitoring, and targeting of biological markers through in vivo studies 225 , 226 . QDs have also been conjugated with many bio-based ligands, mainly including EGFR, prostate-specific membrane antigen, RGD, and folate peptides 227 . Multimodality QDs are already being produced including QDs labeled with RDG peptides for dual-modality fluorescence imaging, based on both PET and near-infrared (NIRF) 228 . The NIRF signal enables increased penetration of the tissue by fluorescence emissions outside the spectral range of the bloodstream or tissue (e.g. autofluorescence) resulting in increased signal-to-background noise coefficients. The PET signal pattern provides an extremely detailed analysis of the tomographic image 229 .

In addition, a further method of optical imaging recognized as Raman spectroscopy has shown considerable advantages in overcoming several fluorescence deficiencies 230 . Raman spectroscopy relies on inelastic light scattering compared to fluorescence, where light absorption occurs. If monochromatic light directly impacts a molecule, (typically through a laser beam, across the near-ultraviolet, NIR, or visible spectrum) any photon may become dispersed. 231 . A Part of the incident photon energy will also be transferred to the molecule, allowing it to oscillate further and contribute to less energy becoming inelastically dispersed by the photon. The "Raman effect" is defined as the exchange of energy between the incident light and the scattering molecule. Because the intensity of the Raman effect is fundamentally poor (about 1 photon is distributed inelastically across all elastically dispersed photons), this restricts the susceptibility and therefore the medicinal implementation of the Raman spectroscopy 232 . Advances across nanoscience have made it possible to synthesize nanomaterials that can solve the problem by reaping the benefits of the surface-enhanced Raman scattering (SERS) effect 233 . SERS is a plasmon-based phenomenon in which an important improvement in the occurrence of an electromagnetic field is observed using adsorbed substances based on noble metals with roughened nano-scale shapes on the surface, which contributes to greater Raman signals. These nanostructures have therefore been developed, containing a roughened center of gold in the range of 60 nanometres, which is covered by a single-layer "Raman organic molecule" with a silica shell in the range of 30 nanometres. The generated field based on electromagnetic associations of the SERS-based organic molecule layer is therefore remarkably enhanced which greatly improves the amplitude of the Raman signal. This enables the identification of nanomaterials across deeper tissues at picomolar concentrations making it a suitable in vivo imaging tool. Each nanomaterial may have its spectral fingerprint. As the organic molecule of Raman alters, it allows several nanomaterials to be observed in vivo at the same time by multiplexing them 234 . This is due to the different chemical bonds of each active layer of Raman, which lead to different molecular-based fluctuations following the excitation of the laser beam. This ends up with a unique signal for each molecule in their Raman signal patterns (Figure ​ (Figure6). 6 ). The latest investigation has shown that nearly 5 spectroscopic fingerprints of biological systems can be detected simultaneously. Therefore, when a specific fingerprint is correlated with a specific nanostructure-bound targeting ligand (e.g. monoclonal antibody, peptide, aptamer, or affibody), cancer molecular profiling can be calculated by spectral analysis of the Raman fingerprints from the tumor. A novel triple modal nanomaterial based on MRI and photoacoustic Raman image processing has recently been produced to facilitate resection and also recognition of brain tumors 234 . Nanostructures enable: 1) full brain tumor placing through MRI using gadolinium covered particles intraoperative and preoperative macroscopic delineation; 2) increased spatial resolution during three-dimensional scanning through its gold center using photoacoustic image analysis; and finally 3) excellent specificity, extremely good resolution, and excellent surface sensitivity through Raman for imaging. Although the possible implementation of SERS and QDs nanomaterials, is proved to be considerable, until we can see their use in conventional clinical settings, concerns about their hazardous toxic properties (in particular the cadmium product) would have to be addressed initially.

A graphic illustration of a nanostructure, based on Raman. Raman nanostructures produce a Raman signal/spectral trace after activation and/or stimulation of the Raman molecular layer: (A) Raman nanostructures are used for multiplexing images; (B) An example of the spectroscopic strength map of the Raman-based nanostructure with SERS effect and ability of tumor targeting.

Nanomaterials have also been widely produced for photoacoustic-based imaging, a special non-ionizing radiation scanning technique that brings about optical and ultrasound visualization 235 . The stated procedure captures nanosecond pulses of infrared light and converts them to dynamic energy. As well, regionalized thermal energy, during which the nanomaterial further produces a wave of RF can be sensed and converted into an ultrasound-like illustration in real-time.

Optical absorption can be correlated either with internal substances (e.g. hemoglobin) or with externally supplied molecules (e.g. SPIONs, nanoclusters, single-walled carbon nanotubes (SWCNTs), and gold nanoparticles) 236 , 237 . Nanomaterial imaging compounds are shown to generate more photoacoustic signaling than smaller substances based on the mole-to-mole ratio 238 . Although these gold nanomaterials were eventually preferred due to their potent absorbance properties and appropriate for monitoring their absorption spectrum (enabling multiplexing techniques), their comparatively large measure leads to accelerated removal of circulation through the RES 239 . However, laboratory experiments using gold and copper nanomaterials provided encouraging results of photoacoustic imaging while visualizing the lymphovascular axillary invasion of breast cancer to classify sentinel lymph nodes 235 , 240 . Even so, due to their unusually high aspect ratio (roughly 1:100) and large surface area, the advancement of SWCNTs as a photoacoustic image processing operator has become of considerable significance 241 . These characteristics reduce their absorption of RES while they are increasingly preferred for molecular targets due to their multivalence effects. Moreover, RGD peptides have been grafted with SWCNTs and used as contrast media for photoacoustic image analysis of tumor mass in a non-invasive manner 242 .

Nanostructures for the design of therapeutic systems

Multifunctional therapeutic nanostructures in future.

Theranostics define the potential within the material, including nanostructures, to be utilized for detection and therapy simultaneously 243 . The aim is to create intelligent nanostructures that provide diagnostic features, targeted therapy, and track the responsiveness of therapeutic interventions within a single interconnected framework. Medication result is expected to improve through the development of these multifunctional nanostructures, with minimized costs and risks. With the advanced polymerization and emulsifying strategies, the hydrophilic and hydrophobic nanomaterials can now be developed, enabling them to be stored in a variety of functional substances (e.g. hydrophobic therapeutic substances, hydrophobic contrast media, etc.) 91 , 244 , 245 .

Regarding anticancer drug candidates, the SPIONs throughout the MRI are studied comprehensively to be treated externally in combination with individual chemotherapy drugs (e.g. trastuzumab, methotrexate, and temozolomide) including mixed hydrophilic and hydrophobic chemotherapy drugs in a double capsule (e.g. paclitaxel and doxorubicin) 246 . More complicated nanoplatforms are being designed using polymer liposomal lipid-coated and tumor-targeting folate-coated lipid coatings that co-encapsulate SPIONs for image processing. Besides, doxorubicin is used for controlled drug release 247 , 248 . Other structures involve the use of SPION cores by a polycation coating layer on the surface (e.g. polyethylene and poly hexamethylene biguanide) that can attach siRNA to form magnetic vectors by electrostatic interactions. This can easily locate on the outer surface of the target cell by the desired magnetic field intensity 249 . This promotes the absorption of the magnetic vector in the endosomes of the cells, thus maximizing the efficacy of siRNA transfection. SPIONs were also modified in the following ways: radiolabelled with 64Cu (for hybrid PET/MRI image processing), RGD-functionalized (for targeting tumor vasculature), and doxorubicin-conjugated (for cancer treatment). Because PET has an extremely good susceptibility, but a relatively low spatial resolution, its conjuncture with MRI can offer remarkably soft tissue images as well as a contrasting spatial resolution that is advantageous but not ideal for CT 250 . In addition, doxorubicin with pH-sensitive properties has been conjugated to PEGylated SPIONs by hydrazone bonds which allow the drug to be released in a controlled manner to the acidic microenvironment surrounding the tumor 251 . However, these novel SPIONs and several other sophisticated nanostructures have been evaluated through cultured cancer cells and have yet to be confirmed for living organisms. However, these promising outcomes bring plenty of positive prospects for the near future. Within the infrared portion of the high-intensity electromagnetic spectral range (e.g. 700 to 1100 nm) where the biological structures have a transparent window, carbon nanotubes (CNTs) are investigated in both optical and photoacoustic image analyses because they have a good optical absorption coefficient 252 . This makes them suitable for tumor treatment with near-infrared photothermal ablation, with a dose and CNT-dependent increase in temperature of the inside of the indicated tumors. Furthermore, since they can quickly cross biological boundaries, CNTs have been studied for their use in the transmission of genes and drugs 253 . Although the process during which the CNTs are accumulated through cells is still not well understood, they may reach and enter the cells regardless of the cell shape and their functional surface groups, CNTs provide the ability to be mixed with chemotherapy drugs such as paclitaxel, doxorubicin, methotrexate, methotrexate, gemcitabine, and cisplatin due to the potential of their spine to construct supramolecular structures 254 . Some researchers have also used CNTs in anticancer immunotherapy 255 , which utilizes CNTs as antigen-presenting vectors to strengthen tumor-dependent poorly immunogenic peptides/antigens to induce tumor response in the humoral immune system 255 , 256 . Cationic CNTs have also been used for both cultured cells and xenograft mice experiments as molecular carriers for siRNA therapy for the suppression/silence of gene expression 257 , 258 . Gold nanomaterials used for photoacoustic and optical image processing can also be used for PTT 193 , 259 . The elevated density of electrons inside the metal-based crystal structure of gold nanostructures leads to photon energy absorption after irradiation, which in turn allows the crystalline structure (and thus the nanostructure) to heat up. The limited diameter and rapid thermal energy conversion potential of gold nanostructures are advantageous for the specific delivery of thermal energy and the subsequent destruction of cancer cells with adequate light resources, even without destruction in the underlying normal tissue. While the NIR-mediated treatment strategy has promising dimensions 260 , its efficacy is restricted by its penetration depth, making it limited to treating mainly superficial tumors close to 2 or 3 cm deep. Even so, gold nanomaterials have already been shown to be less efficient with short-wavelength RF to generate thermal energy, RF-based ablation is still the main solution to the challenge of treating deep-sealed malignancies 261 . Macroscopic electrodes are commonly used to stimulate ablation in RF therapy that appears to be unpleasant in causing long-term adjacent tissue injury. Thus, the use of microelectrodes will make this treatment less aggressive and even more effective if nanomaterials are localized precisely within the mass of the tumor. Multimodal nanostructures have already been developed, such as those with a super magnetic center for MRI image analysis and those with a gold shell layer for PTT 262 .

Other structures include microcapsules with a gold nanoshell to facilitate the utilization of PTT as well as silica-coated gold nanotubes in PTT for the enhancement of the ultrasound imaging, based on contrast media, while the latter also helps to demonstrate better x-ray amplification, including in vivo x-ray and CT image analysis. All of these nanostructures provide strength for the destruction of malignant cells. Once they have been functionalized, they can facilitate targeted selective anti-cancer treatment that can be constantly monitored. Gold nanomaterials are now being developed to contribute to the transport of PTT-specific drugs and genes (e.g. siRNA, DNA, and RNA) to the location of the tumor. Gold nanostructures can be used to improve the drug's water solubility, biocompatibility, durability, and also target tissues in form of loads of photosensitizing substances. Gold nanomaterials are sometimes combined with highly hydrophobic and inadequately hydrophilic photosensitizers, such as phthalocyanine, to increase their therapeutic efficacy. In addition, gold nanomaterials may be used for double-modality therapy with photosensitizers. An example of the latter is the combination of PTT and photodynamic therapy 263 - 268 .

Conclusions

Several different uses for nanostructures in cancer control have been explained throughout this paper. Their specific characteristics have encouraged physicians to improve the clinical efficacy of their cancer treatment strategy either as individual forms of treatment with nanomaterial (monotherapy) or as an adjunct to current therapy (combined treatment). While some nanostructures have not yet proved to be effective for clinical translation, some innovative nanostructures have been effectively designed that suggest promising novel therapeutic benefits for cancer therapy in the immediate future. In both pharmacological and physicochemical aspects, all recently formed nanomaterials, whether or not they are used as carrier materials, it is important to closely monitor their diffusion scale, homogeneity, and accuracy between production batches. In addition, the load-bearing capacity of nanomaterials, mainly the capacity of their polymer ligands and ligand layers must be calculated (for instance, by applying absorption spectroscopy, electron dispersion spectroscopy, electron-based microscopy, etc.). Compared to their corresponding bulk materials, nanomaterials have been shown to have unique characteristics that significantly improve their in vivo application. This is because their limited scale will influence their forms of endocytosis process, cellular transport, and mechanisms of action. Furthermore, their large surface-to-volume proportion, surface-to-surface excitability, and loading capacity may significantly alter their physicochemical characteristics, leading to unintended side effects and adverse biological activities. Although several researchers have assessed the toxic consequences of given nanomaterials, the results remain highly fragile, which may be partly attributable to the varying sizes, shapes, and chemical compositions of nanostructures, as well as the structure of the human cell population being studied. Therefore, both in cultured cells and in live experimental animals, long-term and short-term assessments of toxic effects would have to be carried out until the FDA approves these nanomaterials for clinical application. Nanotechnology, however, has secured creating innovative methods for diagnosis, management, and cancer follow-up throughout the 21 st century alongside our ongoing efforts to combat cancer and our commitment to identify molecular pathways of cancers to achieve early intervention.

Acknowledgments

Shiraz University of Medical Sciences supplied the financials to this work and the above authors contributed equally.